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Jibstract 
The mode of action of the antincancer drugs anthracycline has been examined 
extensively over the past 20 years. Different studies have cited the interaction of the 
inherently reactive drug with DNA, proteins, metal ions, and molecular oxygen, 
leading to an apparently complex interplay of the mechanism of antitumor action, the 
major determinants of which may differ according to the properties of target cancer 
cells (Myers et ai, 1988). Although the reactivities of anthracyclines with a range of 
cellular constituents are well known, but the specific molecular mechanisms involved 
in the plethora of cascade, which ultimately led to tumor cell death are still to be 
elucidated. In this regard, the author has tried to investigate the molecular 
interactions of these drugs with three important targets (i.e. histone, DNA and 
cellular dynamics), which could impact the eukaryotic transcription. 
In cellular environment, eukaryotic genome is condensed within the cell in 
nucleosomes, the primary structural units of chromatin. Nucleosome consists of an 
octameric protein core containing two copies each of histones H2A, H2B, H3 and H4 
and ~200 bp of DNA. The interaction of anthracycline anticancer drugs epirubicin 
(EPI) and mitoxantrone (MTX) with histones and its state of acetylation has been 
extensively studied. We studied the binding of these drugs with core histone and 
histone H3. The features of drug induced structural perturbation of core histones 
were studied by circular dichroism (CD) and absorption spectroscopy. Molecular 
modeling showed that the drugs bind near the N-terminal tail of histone H3. Further 
analysis of the binding site revealed their mode of interaction. The quantitative 
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binding parameters of these drugs with histone H3 have been determined for the first 
time. The mechanism of drug-histone H3 binding was elucidated by steady state 
fluorescence and static type quenching procedure was suggested for this interaction. 
The binding parameters for the reaction have been calculated according to Stem-
Volmer equation at different temperatures, which suggested one high affinity binding 
site with the association constants of the order of lO". The stoichiometry of 
interaction was also evaluated for drug-protein system. The mode of binding was 
expounded by thermodynamic parameters, which entails that hydrophobic 
interactions and hydrogen bonding stabilizes the interaction, which also corroborated 
with the molecular modeling studies. The molecular distance r, between donor 
(histone H3) and acceptor (drug) was estimated according to F'orster's theory of 
non-radiation energy transfer. Further we evaluated the effect of these drugs on the 
enzymatic machinery involved in histone acetylation. We found that EPI and MTX 
both reduces histone acetytransferase (HAT) enzyme activity in a dose- and time-
dependent manner, suggestive of the inhibition of histone acetylation and thereby 
regulated transcription in actively transcribed tumor cell. Interestingly, we also find 
the slight reduction in Histone deacetylase (HDAC) enzyme activity. Though, 
HDACs catalyze the removal of acetyl groups from histones and contribute to 
transcriptional repression but in addition, the HDAC inhibitors induce apoptosis in 
cancer cells through alterations in histone acetylation and activation of the TRAIL 
apoptotic pathway. Also, western blot analysis was performed to determine the 
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pattern and level of H3 acetylation. For this, specific lysine modification was probed 
from nuclear fraction of cancerous cells HEK293 grown with and without the studied 
drugs. Concentration dependent shift in acetylated state of these lysines were 
observed for both the drugs. This deranged equilibrium of histone acetylation can 
lead to alteration in chromatin structure and transcriptional dysregulation of genes 
that are involved in the control of proliferation, cell-cycle progression, differentiation 
and or apoptosis. 
Depletion of histones after covalent modification from chromatin is the key step 
in eukaryotic transcription. The complex disassembles nucleosome structure leading 
to the release of nucleosomal DNA. The majority of anthracyclines administered to 
sensitive tumor cells is known to rapidly localize in the nucleus. The drug has a high 
affinity for DNA, thus providing the driving force for further nuclear uptake. It is 
well known that intercalation is the immediate form of interaction, and there is an 
extensive body of evidence to show that one of the first cellular responses is the 
impairment of topoisomerase II activity. Once a DNA-drug adduct is formed, it is 
widely accepted that the nature of the interaction impedes cellular functions that 
involve DNA (i.e. replication and transcription). But how this interaction occurs, 
does it has any specificity and whether sequence specificity of the drugs governs its 
specific mode of action and interference with specific regulation are still to be 
expounded. Hence, to get the more insight of the interaction of epirubicin (EPI) and 
mitoxantrone (MTX), we have evaluated the associated binding interactions of these 
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anthracyclines with naked DNA. The mechanism of EPI and MTX binding with 
DNA was elucidated by steady state fluorescence and static type quenching 
procedure is suggested for this interaction. The binding parameters for the reaction 
have been calculated according to Stem-Volmer equation at different temperatures, 
which suggests high affinity binding site with the association constants of the order 
of 10 .^ The temperature dependence suggests the destabilization of drug-DNA 
complex. The stoichiometry of interaction was also evaluated. Thermodynamic 
parameters from van't Hoff plots showed that the interaction of these drugs with 
DNA is an entropically driven phenomenon. Binding mode was expounded by UV-
Vis measurements and competitive binding of known intercalator. Sequence 
specificity of these drug-DNA complexes were analysed by fourier transform 
infrared (FTIR) spectroscopy and molecular modeling studies. Circular dichroism 
(CD) spectroscopy and the plasmid nicking assay showed that the binding of these 
drugs results in DNA backbone distortions, resulting in structural and conformational 
transitions. Electrophoretic mobility shift assay (EMSA) was employed to determine 
whether, these drug-DNA complexes prevent binding of transcription factors to DNA 
in tumor cells and also the sequence selectivity of these particular drugs will 
determine which transcription factors are affected, hence, which genes are inhibited. 
This implicate the net effect of this process is that gene-specific inhibition may 
occur, depending on the sequence specificity of the particular drug adducts. 
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To uncover the full spectrum of the pharmacological activities of epirubicin 
(EPI) and mitoxantrone (MTX), we further analyzed their effect of cellular 
machinery, which might depict the profound consequences for the interpretation of 
previous results obtained for these drugs. Also it is a well known fact that 
administration of antitumour anthracycline led to cell death. But again cell death 
can be divided into two main categories, necrosis and apoptosis. Whereas necrosis 
is a catastrophic "death by assault", apoptosis can be thought of as an altruistic 
death, in which a cell positively executes death. Programmed cell death or 
apoptosis is an essential homeostatic mechanism in multicellular organisms 
allowing the elimination of no longer needed or seriously damaged cells by an 
orderly process of cellular disintegration. Depending on the organism, apoptosis 
involves a typical set of morphological events including chromatin condensation, 
DNA and nuclear fragmentation, cell shrinkage, plasma membrane blebbing, 
increased numbers of cytosol vacuoles and formation of apoptotic bodies followed 
by phagocytes digestion. Hence in the last section of this study we have tried to 
address these outcomes for better understanding of epirubicin (EPI) and 
mitoxantrone (MTX) antineoplastic properties. Inhibition on proliferation by these 
drugs was detected by evaluating its effect on cell proliferation and growth curve 
of the cells. EPI and MTX were also found to affect the cell viability and thereby 
affecting the cell physiology. Typical apoptotic morphology such as condensation 
of nuclei in apoptotic cells and inhibition of growth at specific point was observed 
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through confocal laser scanning microscopy (CLSM). The integrity and 
fiinctionality of the yeast plasma membrane at different levels of drug were 
assessed using fluorescence spectroscopy, which is supposed to involve in the 
induction of cell death. As permeabilization of the plasma membranes is the 
critical event and related to cell death. It may result from lipidic phase transitions 
in the membrane and from variations in the area-to-volume ratio during the 
osmotic treatment. Cell cycle distribution was measured by flow cytometric 
measurements. Compared with the control group, the drug treated group exhibit 
differential cell distribution. The analysis demonstrated significant cell-cycle arrest 
with both the drugs. 
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The mode of action of the antincancer drugs anthracycline has been examined 
extensively over the past 20 years. Different studies have cited the interaction of the 
inherently reactive drug with DNA, proteins, metal ions, and molecular oxygen, 
leading to an apparently complex interplay of the mechanism of antitumor action, the 
major determinants of which may differ according to the properties of target cancer 
cells (Myers et ah, 1988). Although the reactivities of anthracyclines with a range of 
cellular constituents are well known, but the specific molecular mechanisms mvolved 
in the plethora of cascade, which ultimately led to tumor cell death are still to be 
elucidated. In this regard, the author has tried to investigate the molecular 
interactions of these drugs with three important targets (i.e. histone, DNA and 
cellular dynamics), which could impact the eukaryotic transcription. 
In cellular environment, eukaryotic genome is condensed within the cell in 
nucleosomes, the primary structural units of chromatin. Nucleosome consists of an 
octameric protein core containing two copies each of histones H2A, H2B, H3 and H4 
and -200 bp of DNA. The interaction of anthracycline anticancer drugs epirubicin 
(EPI) and mitoxantrone (MTX) with histones and its state of acetylation has been 
extensively studied. We studied the binding of these drugs with core histone and 
histone H3. The features of drug induced structural perturbation of core histones 
were studied by circular dichroism (CD) and absorption spectroscopy. Molecular 
modeling showed that the drugs bind near the N-terminal tail of histone H3. Further 
analysis of the binding site revealed their mode of interaction. The quantitative 
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binding parameters of these drugs with histone H3 have been determined for the first 
time. The mechanism of drug-histone H3 binding was elucidated by steady state 
fluorescence and static type quenching procedure was suggested for this interaction. 
The binding parameters for the reaction have been calculated according to Stem-
Volmer equation at different temperatures, which suggested one high affinity binding 
site with the association constants of the order of lO". The stoichiometry of 
interaction was also evaluated for drug-protein system. The mode of binding was 
expounded by thermodynamic parameters, which entails that hydrophobic 
interactions and hydrogen bonding stabilizes the interaction, which also corroborated 
with the molecular modeling studies. The molecular distance r, between donor 
(histone H3) and acceptor (drug) was estimated according to F'orster's theory of 
non-radiation energy transfer. Further we evaluated the effect of these drugs on the 
enzymatic machinery involved in histone acetylation. We found that EPI and MTX 
both reduces histone acetytransferase (HAT) enzyme activity in a dose- and time-
dependent manner, suggestive of the inhibition of histone acetylation and thereby 
regulated transcription in actively transcribed tumor cell. Interestingly, we also find 
the slight reduction in Histone deacetylase (HDAC) enzyme activity. Though, 
HDACs catalyze the removal of acetyl groups fi-om histones and contribute to 
transcriptional repression but in addition, the HDAC inhibitors induce apoptosis in 
cancer cells through alterations in histone acetylation and activation of the TRAIL 
apoptotic pathway. Also, western blot analysis was performed to determine the 
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drugs. Concentration dependent shift in acetylated state of these lysines were 
observed for both the drugs. This deranged equilibrium of histone acetylation can 
lead to alteration in chromatin structure and transcriptional dysregulation of genes 
that are involved in the control of proliferation, cell-cycle progression, differentiation 
and or apoptosis. 
Depletion of histones after covalent modification from chromatin is the key step 
in eukaryotic transcription. The complex disassembles nucleosome structure leading 
to the release of nucleosomal DNA. The majority of anthracyclines administered to 
sensitive tumor cells is known to rapidly localize in the nucleus. The drug has a high 
affinity for DNA, thus providing the driving force for fiirther nuclear uptake. It is 
well known that intercalation is the immediate form of interaction, and there is an 
extensive body of evidence to show that one of the first cellular responses is the 
impairment of topoisomerase II activity. Once a DNA-drug adduct is formed, it is 
widely accepted that the nature of the interaction impedes cellular fiinctions that 
involve DNA (i.e. replication and transcription). But how this interaction occurs, 
does it has any specificity and whether sequence specificity of the drugs governs its 
specific mode of action and interference with specific regulation are still to be 
expounded. Hence, to get the more insight of the interaction of epirubicin (EPI) and 
mitoxantrone (MTX), we have evaluated the associated binding interactions of these 
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anthracyclines with naked DNA. The mechanism of EPI and MTX binding with 
DNA was elucidated by steady state fluorescence and static type quenching 
procedure is suggested for this interaction. The binding parameters for the reaction 
have been calculated according to Stem-Volmer equation at different temperatures, 
which suggests high affinity binding site with the association constants of the order 
of 10 .^ The temperature dependence suggests the destabilization of drug-DNA 
complex. The stoichiometry of interaction was also evaluated. Thermodynamic 
parameters from van't Hoff plots showed that the interaction of these drugs with 
DNA is an entropically driven phenomenon. Binding mode was expounded by UV-
Vis measurements and competitive binding of known intercalator. Sequence 
specificity of these drug-DNA complexes were analysed by fourier transform 
infrared (FTIR) spectroscopy and molecular modeling studies. Circular dichroism 
(CD) spectroscopy and the plasmid nicking assay showed that the binding of these 
drugs results in DNA backbone distortions, resulting in structural and conformational 
transitions. Electrophoretic mobility shift assay (EMSA) was employed to determine 
whether, these drug-DNA complexes prevent binding of transcription factors to DNA 
in tumor cells and also the sequence selectivity of these particular drugs will 
determine which transcription factors are affected, hence, which genes are inhibited. 
This implicate the net effect of this process is that gene-specific inhibition may 
occur, depending on the sequence specificity of the particular drug adducts. 
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To uncover the full spectrum of the pharmacological activities of epirubicin 
(EPI) and mitoxantrone (MTX), we fiirther analyzed their effect of cellular 
machinery, which might depict the profound consequences for the interpretation of 
previous results obtained for these drugs. Also it is a well known fact that 
administration of antitumour anthracycline led to cell death. But again cell death 
can be divided into two main categories, necrosis and apoptosis. Whereas necrosis 
is a catastrophic "death by assault", apoptosis can be thought of as an altruistic 
death, in which a cell positively executes death. Programmed cell death or 
apoptosis is an essential homeostatic mechanism in multicellular organisms 
allowing the elimination of no longer needed or seriously damaged cells by an 
orderly process of cellular disintegration. Depending on the organism, apoptosis 
involves a typical set of morphological events including chromatin condensation, 
DNA and nuclear fragmentation, cell shrinkage, plasma membrane blebbing, 
increased numbers of cytosol vacuoles and formation of apoptotic bodies followed 
by phagocytes digestion. Hence in the last section of this study we have tried to 
address these outcomes for better understanding of epirubicin (EPI) and 
mitoxantrone (MTX) antineoplastic properties. Inhibition on proliferation by these 
drugs was detected by evaluating its effect on cell proliferation and growth curve 
of the cells. EPI and MTX were also found to affect the cell viability and thereby 
affecting the cell physiology. Typical apoptotic morphology such as condensation 
of nuclei in apoptotic cells and inhibition of growth at specific point was observed 
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through confocal laser scanning microscopy (CLSM). The integrity and 
functionality of the yeast plasma membrane at different levels of drug were 
assessed using fluorescence spectroscopy, which is supposed to involve in the 
induction of cell death. As permeabilization of the plasma membranes is the 
critical event and related to cell death. It may result from lipidic phase transitions 
in the membrane and fi-om variations in the area-to-volume ratio during the 
osmotic treatment. Cell cycle distribution was measured by flow cytometric 
measurements. Compared with the control group, the drug treated group exhibit 
differential cell distribution. The analysis demonstrated significant cell-cycle arrest 
with both the drugs. 
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1.1 Anthracycline antibiotics 
Anthracyclines rank among the most effective anticancer drugs ever 
developed (Weiss, 1992). The first anthracyclines were isolated from the 
pigment-producing Streptomyces peucetius early in the 1960s and v/ere 
named doxorubicin (DOX) and daunorubicin (DNR). They share aglyconic a 
tetracyclic ring with adjacent quinone-hydroquinone groups in rings C-B, a 
methoxy substituent at C-4 in ring D, and a short side chain at C-9 with a 
carbonyl at C-13. The sugar, called daunosamine. Is attached (except 
mitoxantrone) by a glycosidic bond to the C-7 of ring A and consists of a 3-
amino-2,3,6-trideoxy-L-fucosyl moiety. The only difference between DOX and 
DNR is that the side chain of DOX terminates with a primary alcohol, whereas 
that of DNR terminates with a methyl. This minor difference has important 
consequences on the spectrum of activity of DOX and DNR. Whereas DOX is 
an essential component of treatment of breast cancer, childhood solid 
tumors, soft tissue sarcomas, and aggressive lymphomas, DNR shows activity 
in acute lymphoblastic or myeloblastic leukemias. As with any other 
anticancer agent, however, the clinical use of both DOX and DNR soon proved 
to be hampered by such serious problems as the development of resistance in 
tumor cells or toxicity in healthy tissues, most notably in the form of chronic 
cardiomyopathy and congestive heart failure (CHF). To avoid the latter, the 
maximum recommended cumulative doses of DNR and DOX were tentatively 
set at 500 or 450 to 600 mg/m^ respectively. The last 2 decades have 
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witnessed numerous attempts to identifying novel anthracydines that proved 
superior to DOX or DNR in terms of activity and/or cardiac tolerability (Weiss, 
1992). The search for a "better anthracycline" has resulted in some 2000 
analogs, a figure that should not sound like a surprise if one considers the 
number of chemical modifications or substitutions and/or conjugations that 
can be introduced in the tetracyclic ring, the side chain, or the aminosugar. 
Yet only few analogs have reached the stage of clinical development and 
approval; among them, epirubicin (EPI) and mitoxantrone (MTX) enjoy 
popularity as alternatives due to their usefulness and less toxicity, 
respectively. 
EPI is a semisynthetic derivative of DOX obtained by an axial-to-
equatorial epimerization of the hydroxyl group at C-4' in daunosamine. This 
positional change has little effect on the mode of action and spectrum of 
activity of EPI compared with DOX, but it introduces pharmacokinetic and 
metabolic changes like increased volume of distribution (Vd), 4-0-
glucuronidation, and consequent enhanced total body clearance (CL) or 
shorter terminal half-life (Robert & Gianni, 1993; Danesi et al., 2002). It is 
because of these kinetic and metabolic changes that EPI was soon used at 
cumulative doses almost double those of DOX, resulting in equal activity but 
not in increased cardiotoxicity (Robert, 1993). In practice, early studies of 
patients with advanced breast cancer demonstrated that the median doses to 
the development of laboratory indices of cardiotoxicity were 935 mg/m^ EPI 
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compared with 468 mg/m^ DOX, and the median cumulative dose to the 
development of symptomatic CHF was 1134 mg/m^ EPI compared with 492 
mg/m DOX (Jain ef o/., 1985). This data was refined in subsequent studies, 
since a significantly increasing risk of CHF was documented in patients who 
received cumulative doses greater than 950 mg/m^ and the recommended 
maximum cumulative dose of EPI was cautiously adjusted to 900 mg/m^ 
(Ryberg etai, 1998). Thus, replacing DOX with EPI does not eliminate the risk 
of developing chronic cardiotoxicity. It should also be noted that the 
mechanisms underlying the reduced cardiotoxicity of EPI versus DOX might 
not be confined to glucuronidation and increased elimination. The actual 
mechanisms and dose dependence of the improved cardiac tolerability of EPI 
may therefore require further assessment in both preclinical and clinical 
settings. 
Mitoxantrone (MTX), an analogue of the anthracycline antibiotics, 
belongs to the anthracenediones, a class of synthetic chemotherapeutic 
agents. The mode of action of MTX has not yet been clearly established. It 
includes, among others, intercalation and binding to DNA, bioreduction and 
aerobic redox cycling (Barasch et al., 1999). The drug exhibits a range of 
intracellular effects, the most dominant of which appears to be the induction 
of DNA damage. This may relate to the ability of MTX to cause inter- and 
intrastrand cross-linking and also to intercalate into DNA and trigger 
topoisomerase ll-dependent DNA cleavage with the production of both single 
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and double-strand breaks (Fox and Smith, 1995; Marker et al., 1995). In 
microbial mutagenicity tests, MTX caused frameshift mutation (Westendorf et 
al., 1985), consistent with intercalation in the DNA molecule (Panousis and 
Phillips, 1994). MTX proved to be genotoxic only in cellular systems, 
suggesting that metabolism of the drug is a necessary step leading to DNA 
damage (Skladanowski and Konopa, 2000). Oxidatively activated MTX, results 
in covalent incorporation of the drug into cellular DNA (Mewes et al., 1993; 
Panousis et al., 1997). 
These introductory remarks on the activity and toxicity of most 
commonly used anthracyclines are meant to indicate that a better 
anthracycline has yet to come. It is therefore not surprising that relatively old 
drugs like DOX and DNR remain the focus of clinical and preclinical research 
aimed at improving our appraisal of their mechanisms of activity or toxicity 
and at identifying new strategies for better use in cancer patients. Likewise, 
the search for new analogs or formulations continues unabated. In preparing 
for this, several seminal reviews have appeared over the last 2 or 3 years and 
focused on the same or closely related subjects. Authoritative analyses of the 
mechanisms of action of anthracyclines have been provided by Binaschi et al. 
(2001), Laurent and Jaffrezou (2001), Perego et al. (2001), and Kim et al. 
(2002b), among others. 
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Figure 1.1 Chemical structure of anthracydine antibiotic epirubicin (EPI). 
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Figure 1.2 Chemical structure of anthracycline antibiotic mitoxantrone (MTX). 
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Molecular mechanisms and pharmacological or clinical correlates of 
anthracycline-induced cardiotoxicity have been reviewed by Myers (1998), 
Singal et al. (2000), Kalyanaraman et al. (2002), and Zucchi & Danes! (2003), 
among others. The pharmacokinetic-pharmacodynamic relationships of 
anthracycline activity or toxicity have been reviewed by Danesi et al. (2002), 
and progress in the pharmaceutical designing of new anthracyclines has been 
reviewed by Monneret (2001), among others. Finally, mechanisms of tumor 
resistance and possible methods for overcoming them have been reviewed by 
Benjamin et al. (2000), Tan et al. (2000), Lothstein et al. (2001), and Ejendal & 
Hrycyna (2002). 
1.2 Antitumor activity of anthracyclines 
1.2.1 General considerations 
Despite extensive clinical utilization, the mechanisms of action of 
anthracyclines in cancer cells remain a matter of controversy. In a seminal 
commentary the following mechanisms were considered: 1) intercalation into 
DNA, leading to inhibition of macromolecule synthesis; 2) generation of free 
radicals, leading to DNA damage or lipid peroxidation; 3) DNA binding and 
alkylation; 4) DNA cross-linking; 5) interference with DNA unwinding or DNA 
strand separation and helicase activity; 6) direct membrane effects; 7) 
initiation of DNA damage via inhibition of topoisomerase II; and 8) induction 
of apoptosis in response to topoisomerase II inhibition (Gewirtz, 1999). An 
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experiments reported in the literature had been performed at concentrations 
of DOX which were considered too high compared with peal< or steady-state 
plasma concentrations {Cmax, Qs) observed in patients after standard bolus 
infusions (~5 nM and 25-250 nM, respectively). It was therefore concluded 
that any study involving intact cells exposed to >1 to 2 nM DOX needed a 
cautionary re-evaluation. The same cautionary issue was considered in 
examining studies with subcellular fractions, often performed with 
submillimolar concentrations of anthracyclines (Gewirtz, 1999). When 
examined in this context, topoisomerase II remains an attractive and 
persuasive mechanism to explain the antitumor activity of DOX and other 
approved anthracyclines at clinically relevant concentrations 
1.2.2 Anthracycrmes as topoisomerase II poisons. 
Topoisomerases modify the topology of DNA without altering 
deoxynucleotide structure and sequence. They can cause transient single-
strand (topoisomerase I) or double-strand (topoisomerase II) DNA breaks that 
are reseated after changing the twisting state of the double helix. This activity 
confers an important role on topoisomerases as the supercoiling of the DNA 
double helix is modulated according to the cell cycle phase and transcriptional 
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activity (Binaschi et al., 2001). Anthracydlnes act by stabilizing a reaction 
intermediate in whicli DNA strands are cut and covalently linl<ed to tyrosine 
residues of topoisomerase II, eventually impeding DNA resealing. The 
formation and stability of an anthracycline-DNA-topoisomerase II ternary 
complex rely on defined structural determinants. The planar ring system is 
important for intercalation into DNA, as rings B and C overlap with adjacent 
base pairs and ring D passes through the intercalation site. The external 
(nonintercalating) moieties of the anthracycline molecule (i.e., the sugar 
residue and the cyclohexane ring A) seem to play an important role in the 
formation and stabilization of the ternary complex, in particular, the sugar 
moiety, located in the minor groove, is a critical determinant of the activity of 
anthracyclines as topoisomerase II poisons. Topoisomerase II inhibition 
increases after removal of aminosubstituents at C-3' in the sugar or of the 
methoxy group at C-4 in ring D (as already mentioned for IDA); moreover, the 
nature of 3'-substituents greatly influences the sequence selectivity of 
anthracycline-stimulated DNA cleavage (Binaschi et al., 2000, 2001). 
Doxorubicin has been reported to also inhibit topoisomerase I, an effect 
shared by IDA and investigational IDA analogs bearing a disaccharide moiety 
in which the second sugar retains an axial orientation relative to the first one 
(Guano ef al., 1999). The cell-killing activity of anthracyclines is weakly but 
significantly dependent on cellular topoisomerase I content, suggesting that 
inhibition of topoisomerase I may represent an ancillary mode of action of 
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anthracyclines (Guano et ai, 1999). Topoisomerase ll-mediated DNA damage 
is followed by growth arrest in Gi and G2 and programmed cell death (Perego 
et al., 2001; Zunino et al., 2001). It follows that tumor cells may become 
resistant to anthracyclines because of altered topoisomerase II gene 
expression or activity (Lage et al., 2000). In clinical settings, the degree of 
apoptosis induction correlates with tumor response and patient's outcome 
(Buchholz et al., 2003). 
1.2.3. Role of the proteasome 
Proteasomes are cytoplasmic and nuclear proteinase complexes involved 
in non lysosomal mechanisms of protein degradation. The 26S proteasome 
(composed of a 20S core particle and two 19S cap structures) plays a crucial 
role in the normal turnover of cytosolic and nuclear proteins and also plays a 
role in the processing and degradation of regulatory proteins that control cell 
growth and metabolism (Adams, 2003; Cusack, 2003). The last few years have 
witnessed an emerging role of the proteasome in modulating anthracycline 
activity. Proteasomes are present both in the nucleus and in the cytoplasm, 
but transformed cells and proliferating tissues usually exhibit a preferential 
accumulation of the proteasome in the nucleus (Kiyomiya et al., 2001b). 
Conditions typical of solid tumors (like glucose starvation or hypoxia) may 
accentuate nuclear localization of the proteasome, probably through an 
increased expression of nuclear localization signals in the o-type subunits of 
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the 20S proteasome. In xenografted human tumors, this is accompanied by 
development of the resistance phenotype, mediated by proteasome 
degradation of topoisomerase II and reverted by administration of 
proteasome inhibitors (Ogiso etai, 2000). 
1.2.4 Role of free radicals 
One-electron addition to the quinone moiety in ring C of DOX and other 
anthracyclines has long been known to result in formation of a semiquinone 
that quickly regenerates its parent quinone by reducing oxygen to reactive 
oxygen species (ROS) like superoxide anion (02-') and hydrogen peroxide 
(H2O2). This futile cycle is supported by a number of NAD(P)H-oxidoreductases 
[cytochrome P450 or -b^ reductases, mitochondrial NADH dehydrogenase, 
xanthine dehydrogenase, endothelial nitric oxide synthase (reductase 
domain)] (Vasquez-Vivar et o/., 1997). During this cycle the semiquinone can 
also oxidize with the bond between ring A and daunosamine, resulting in 
reductive deglycosidation and formation of 7-deoxyaglycone. Due to their 
increased lipid solubility, aglycones intercalate into biologic membranes and 
form ROS in the closest proximity to sensitive targets (Licata et al., 2000). One-
electron redox cycling of DOX is also accompanied by a release of iron from 
intracellular stores (ligand binding interactions of DOX with released iron then 
result in formation of 3:1 drug-iron complexes that convert Or' and H2O2 into 
more potent hydroxy! radicals (-OH) (Minotti et al., 1999). Oxidative damage 
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has therefore been considered an important mechanism of anthracycline 
activity in tumor cells. Although no doubt exists about whether DOX and 
other anthracyclines possess the chemical requisites to generate free radicals 
in cancer cells, too often this is seen at supraclinical drug concentrations. In 
those cases when cancer cells were exposed to clinically relevant 
concentrations of DOX, there was a long lag phase between drug 
administration and detection, e.g., of H2O2. Concentrations of anthracyclines 
below 5 ^M, and hence of potential clinical significance, caused formation of 
protein-associated DNA single- and double-strand breaks, which reflected 
anthracycline inhibition of topoisomerase II; in contrast, the formation of 
nonprotein-associated strand breaks, i.e., DNA lesions caused by free radical 
formation and reactivity on the DNA backbone, only occurred when the cells 
were treated with supraclinical concentrations of DOX (reviewed by Gewirtz, 
1999). 
« 
1.2.5 Anthracycline-formaldehyde conjugates 
Anthracyclines have long been known to form unstable covalent bonds to 
DNA when redox-activated in chemical systems with NAD(P)H 
oxidoreductases and transition metals. Seminal work by Taatjes, Koch, and 
associates has led to an-in-depth reappraisal of this picture. They have shown 
that iron-mediated free radical reactions enable anthracyclines to produce 
formaldehyde (HCHO-form) from carbon cellular sources like spermine and 
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lipids (Taatjes et al., 1997, Taatjes & Koch, 2001). Elevated levels of HCHO 
have been detected in DOX-sensitive cancer cells but not in DOX-resistant 
cancer cells equipped with higher levels of ROS-detoxifying enzymes (Kato et 
al., 2001). Doxorubicin and HCHO then react to give a conjugate (DOX-form) in 
which two anthracycline molecules bind together with three methylene 
groups, two forming oxazolidine rings and one binding the oxazolidines 
together at their 3'-amino nitrogens. DOX-form eventually hydrolyzes to give 
an active monomeric metabolite in which the carbon of HCHO is recovered in 
the form of a Schiff's base at the aminogroup of daunosamine. Similar 
reactions occur with EPI but not with anthracyclines lacking a 3'-amino group 
(Cutts et al., 2003). 
1.2.6 Anthracyclines and telomeric DNA. 
Telomeres are the ends of linear chromosomes of eukaryotic cells. In 
most eukaryotes, telomeres consist of as many as 500 to 3000 5'-TTAGGG-3' 
repeats and serve to protect the end of chromosomes from degradation and 
ligation. The length of telomeres is primarily controlled by telomerase, a 
ribonucleoprotein composed of a catalytic protein subunit (telomerase 
reverse transcriptase, TERT), a telomerase-associated protein, and a stably 
associated RNA moiety, which serves the function of an intrinsic template for 
the elongation of telomeres. It has been well established that telomerase is 
not active in most somatic tissues; therefore, telomeres shorten gradually 
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with age, both in vitro and in vivo, and such erosion is sensed by the cells as a 
clock to switch toward a p53-mediated senescence program (Chin et al., 
1999). Conversely, telomerase is activated in the majority of cancer-derived 
cell lines and malignant tumors, a finding suggesting that telomerase is pivotal 
to cell immortalization and tumorigenesis or tumor aggressiveness. 
Supportive evidence is offered by, among several other reports, increased 
development of breast cancer in transgenic mice overexpressing mTERT 
(Artandi et al., 2002); induction of massive apoptosis in human acute 
leukemia cells transfected with a dominant-negative human TERT; inverse 
correlation between telomerase activity and overall or disease-free survival in 
lung carcinoma patients (Marchetti et al., 2002); positive correlation between 
attenuation of telomerase activity and inhibition of cellular growth or 
induction of apoptosis in immortal breast cancer cell lines transiently 
transfected with hammerhead ribozyme cleaving human TERT mRNA (Ludwig 
et al., 2001). 
Interestingly, telomeres do not always shorten after telomerase inhibition 
and consequent induction of apoptosis. This suggests the existence of 
telomerase-independent mechanisms of telomere elongation (Kim et al., 
2002a); it also suggests that telomerase may extend the lifespan of the cell by 
alternative mechanisms such as capping of free G-rich single-stranded 
telomeric DNA, which otherwise would become exposed to the nucleoplasm 
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and could trigger cell cycle arrest or apoptosis, depending on the cellular 
context (Ludwig et al., 2001). 
1.3 ONA-ligand interactions 
DNA as a carrier of genetic information is an important target for drug 
interaction as the bound drugs may interfere with the gene expression, DNA 
replication, cell growth and division. The aromatic ligands interact with DNA 
double helix by intercalation between stacked bases and binding to minor 
grooves. The available evidence indicates that the anthracyclines antibiotics 
bind to DNA either through intercalation of hydroxyquinine portion of the 
drugs and/or by electrostatic interactions. Intercalation of hydrophobic 
chromophore between adjacent DNA base pairs is thought to be the 
predominant mode of anthracycline-DNA interaction and has been 
extensively studied (Pigram ef al., 1972; Gabbay et al.; 1976). However the 
electrostatic binding, which is a weaker mode of binding than intercalation, 
consists of an ionic interaction between the amino group on the anthracycline 
amino sugar and phosphates on DNA backbone ( Pigram et al., 1972; Patel & 
Canuel, 1978). Certain drugs including adriamycin interfere with DNA function 
by chemically modifying specific nucleotides. The antibiotic anthramycin is an 
antitumor agent, which binds covalently to N-2 of guanine located in the 
minor groove of DNA. It has a preference of purine-G-purine sequences with 
bonding to the middle G. The interaction of DNA with cations, amino acids 
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and nucleotides becomes a matter of interest because of implications in the 
biological functioning of DNA. The binding of various dyes, drugs and 
antibiotics to DNA and chromatin have contributed to an understanding of 
the structure of these macromolecuies and have suggested the possible 
mechanisms of biological activity of some drugs (Goldberg et ai, 1977). 
1.4 Epigenetics 
Epigenetics is the study of reversible heritable changes in gene function 
that occur without a change in nucleotide sequence of the DNA; therefore, 
gene function is not only determined by the DNA code but also by epigenetic 
phenomena. Over the past fifteen years, it has been shown that gene 
expression can be regulated by the proteins called histones, which help 
packing genomic DNA into the nucleus and also by enzymes that modify both 
histones and the DNA (Antoneilo et o/, 2005; Fire, 1998). The two main 
mechanisms in the epigenetic regulation of gene expression involve DNA 
methylation and histone modifications. The study of these mechanisms is 
important since the change of gene expression is implicated in numerous 
human disorders and diseases, including obesity, diabetes, cancer and 
developmental abnormalities (Feinberg, 2001). 
1.4.1 Histones and chromatin structure 
In 1884 histones were discovered by Albrecht Kossel. The word "histone" 
comes from the German word of "Histone", of uncertain origin and perhaps 
from Greel< word histanai or histos. Until the early 1990s, histones were 
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known just as packing material for nuclear DNA. The regulatory functions of 
histones were discovered during the early 1990s. It is now known that 
histones are small basic architectural proteins of 102-135 amino acids that 
package the genomic DNA of eukaryotic organism into chromatin which is a 
dynamic macromolecular complex (Harmit & Steven, 2003). The basic 
repeating units of chromatin, the nudeosome, is composed of two super 
helical turns of DNA containing approximately 146 base pairs which wrap 
around an octamer of the four core histones H2A, H2B, H3,and H4 with the 
addition of linker DNA and histone HI. HI determines the level of DNA 
condensation (Patrick, 2001). These highly conserved histone proteins play an 
important role in determining the structure and function of chromatin which 
can be dynamically changed. 
Chromatin condensation provides an extensive barrier to the 
nuclear machinery that drives processes such as replication, transcription, or 
DNA repair; while chromatin decondensation facilitates those processes. Each 
core histone protein has two domains: a histone fold domain or globular 
domain, which is involved in histone-histone interactions as well as in 
wrapping DNA in nucleosomes; and a more flexible and charged amino 
terminal 'tail' domain of 25-40 residues (Patrick, 2001). The tail lies on the 
outside of the nudeosome where it can interact with other regulatory 
proteins and with DNA. The basic N terminal tails of the core histones are 
subject to various post-translational modifications. The functional effects of 
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tail modifications are dependent on the specific amino acids that are 
modified. The selected amino acid residues of the core histones (H3-H4)2 
tetramer are modified by acetylation (AC), methylation (Me), and 
phosphorylation (P); and H2A-H2B dimers are modified by acetylation, 
phosphorylation, ubiquitination (Ub), multiubiquitination, and AOP-
ribosylation. The function of these modifications is the focus of attention due 
to the possibility that the nucleosome, with its modified tail domains, is not 
only a packer of DNA but also a carrier of epigenetic information that 
indicates both how genes are expressed as well as how their expression 
patterns are maintained from one cell generation to the next. Of 3 such 
modifications, acetylation and deacetylation have generated the most 
interest. Also acetylation was the first modification that had been reported to 
have correlation with gene activity (Allfrey ef o/, 1964). 
1.4.2 Histone acetylation, deacetylation and chromatin structure 
In order to understand the role of acetylation in transcriptional 
regulation, it would be beneficial to know what structural changes may occur 
within chromatin as a result of acetylation and/or deacetylation. Currently 
two theories exist that postulate how histone acetylation may facilitate 
transcription. The first theory proposes that acetylation neutralizes the 
positive charge on histones, thereby reducing the affinity between histones 
and DNA, and relaxing chromatin (Workman et al, 1998), as depicted in 
figure.1.3. Therefore, histone acetylation facilitates the access of 
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Transcription Factors (TFs), and RNA polymerases to promoter regions of DNA 
(Struhl, 1998) and allows transcriptional activation. A second theory suggests 
that covalent modification of histones provides an epigenetic marker for gene 
expression known as "histone code" (Strahl et al, 2000) or 'epigenetic code' 
(Jenuwein and Allis, 2001; Turner, 2000). In other words the level of affinity of 
chromatin for chromatin - associated proteins may depend on particular 
pattern of histone modifications in a cell which determines if chromatin is in 
an active "euchromatin" or silent "heterochromatin" state. Histone tails may 
be involved in the arrangement of higher order chromatin structure and 
acetylation may facilitate its disruption. Acetylation of H3 and H4 tails, the 
dominant factor in maintaining chromatin conformation, may disrupt higher 
order structure rather than to destabilize the histone - DNA interaction within 
the nucleosome (James, 1998). 
A positive charge on lysine residues of core histones is restored by 
histone deacetylation, permitting chromatin to change into a highly 
condensed, transcriptionally silent conformation or heterochromatin. 
Therefore, in most cases, histone acetylation derepress transcription while 
histone deacetylation represses transcription. Nevertheless, in some cases 
transcriptional repression occurs as a result of histone acetylation which can 
be possibly explained by the histone code hypothesis. The balance between 
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Figure.1.3 Histone acetylation and transition of heterochromatin to 
euchromatin. The figure depicts the molecular structure of acetylated and 
deacetylated lysine and the resultant charges/neutralization responsible for 
the interaction of histones with chromatin 
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histone acetylation/deacetylation is controlled by the competitive activities of 
2 superfamilies of enzymes: histone acetyltransferases (HATs) and histone 
deacetylases (HDACs) (James, 1998). 
1.4.3 Histone acetylation and gene transcription 
The very first indication of association between acetylation and 
transcription came from the observation of Allfrey and co-workers who 
proposed that in actively transcribed regions of chromatin, histones tend to 
be hyperacetylated, whereas in transcriptionally silent regions histones are 
hypoacetylated. Many additional studies have solidified this proposal by 
showing that hyperacetylated core histones are associated with 
transcriptionally active chromatin (Brownell et al., 1996; Vettese-Dadey etal., 
1996). Two independent lines of evidences exist that suggested the 
acetylation and transcription may be mechanistically and physiologically 
related. First, in yeast, altered patterns of transcription due to the mutation 
of H4 lysine residues have been reported. Those mutations prevented the 
acetylation of the H4 tail (Durrin et al., 1991). Second, treatment of 
mammalian cells with effective inhibitors of histone deacetylase activity, such 
as trapoxin and trichostatin A, resulted in augmented expression of a diversity 
of genes (Yoshida et al., 1995). However, after identification of the structure 
and function of a variety of histone acetyltransferases and deacetylases the 
molecular mechanisms of these processes became clearer. The interesting 
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part of these findings is that numerous HATs and HDACs are proteins, initially 
characterized as being involved in transcriptional regulation. 
1.4.4 Histone acetyltransferase (HAT) 
An early indication that histone acetyltransferases (HAT) are involved in 
transcription came from the discovery of a protein p55 in tetrahymena 
(Kouzarides et ai, 1995). P55 is related to yeast protein, GCN5 (transcriptional 
coactivator/adapter), and was found to acetylate histones (Durrin et ai, 
1991). Currently, numerous co-activator proteins are known to have HAT 
activity. HAT which links chromatin modification to gene activation, is the 
catalytic subunit of a multi-subunit protein complex (Jenuwein and Allis, 
2001) that catalyzes the transfer of an acetyl group from acetyl-CoA to the 
specific lysine residues on the N-terminal regions of the histones. All HATs 
contain an acetyltransferase domain, and a shared domain that can be used 
to group HATs into subfamilies (Yoshida ef ai, 1995). Sequence analysis of 
HAT proteins shows that they contain a high sequence similarity within 
families but little to no sequence similarity between families (Kouzarides ef 
ai, 1995). Furthermore, each HAT family has a distinct substrate preference, 
and different families are in different functional contexts. Typically, HATs 
acetylate global histones or nudeosome substrates. In most cases, the ability 
to acetylate nudeosome substrates reflects a role for HAT in chromatin 
modification. The ability of HATs to acetylate only global histones may reflect 
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a role in nucleosome assembly. There have been five families of histone 
acetyltransferases reported which contain more than twenty enzymes. 
1.4.5 Histone acetylation and diseases 
It is hypothesized that different diseases can be the result of 
hyperacetylation of chromosomal regions that are generally silenced or 
deacetylation of chromosomal regions that are generally actively transcribed; 
therefore, alterations of HATs and HDACs at the genomic level disturb the 
equilibrium of histone acetylation and deacetylation which in turn acts as a 
key factor in regulating gene expression and guide the cell to either 
proliferate or differentiate (Fig.l.4.[also reviewed by the author]). Review of 
some of the diseases associated with aberrant HAT and / or HDACs activity 
can further supports this hypothesis. Mutations in the human CBP gene have 
been reported to be associated with rubinstein-taybi syndrome (RTS) which is 
a developmental haploinsufficiency disorder with an increased risk of cancer 
development (Gennaro ef ai, 2004; Murata et al., 2001). In human cancer, 
spontaneously occurring mutations in the P300 gene have been reported 
(Eckner et al., 1994; Muraoka et al., 1996), which reinforce the idea that 
indicate 'P300/CBP activity can be under abnormal control in human disease, 
particularly in cancer, which may inactivate a p300/CBP tumor-suppressor-like 
activity (Goodman and Smolik, 2000). PCAF can interact with two important 
cell cycle regulators: E2F and p53. Transcription factor E2F induces S-phase 
specific gene expression and is involved in promoting S-phase-entry. In 
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Figure.1.4 Model depicting the role of histone acetylation in regulation of 
cellular development, (a).The heterodimerization of cell cycle regulatory 
factors Max with transcriptional activator Myc supports the formation of 
multiprotein complex and recruitment of histone acetyltransferase. Thereby, 
enhancing acetylation and accessibility of chromatin to transcription factors, 
this enhances the transcription. (b).The homodimerization of regulatory 
factor Max maintains the basal cellular transcription. (c).The association of 
regulatory factor Max with Mad leads to the recruitment of HDAC complex, 
which deacetylases the histones resulting in condense heterochromatin state 
and hence, the condensed form of chromatin could not provide accessibility 
to transcription factors and eventually, it represses the transcription, (model 
in process of publication). 
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contrast, p53 acts as a tumor suppressor protein by inhibiting cell cycle 
progression and S-phase entry. Induction of p53 usually leads to 
posttranslational modifications of the protein (Liu et o/., 1999). Several 
reports have been shown that acetylation of the C-terminal regulatory 
domain is involved in regulating activity of p53 (Sakaguchi et o/., 1998; Egan et 
o/., 1988). Acetylation of this site is observed after DNA damage in m\jo, 
induced p53 and caused cell cycle arrest or apoptosis; therefore, over 
expression of PCAF can cause growth arrest (Gennaro et a\., 2004). On the 
other hand acetylation of E2F increases the transcriptional activity of E2F in 
vivo and stabilizes the E2F protein (Gennaro et o/., 2004). Therefore, PCAF can 
be involved in two opposing scenarios: one is promoting of cell cycle 
progression by activating E2F, the other is cell cycle arresting by activating 
p53. Thus, significant effects on cellular proliferation and tumor formation 
can be the result of PCAF mutation. 
1.4.6 Histone deacetylases (HOAC) 
The identification of several histone deacetylase (HDAC) enzymes (Gray & 
Ekstrom, 2001), whose activities have been correlated with transcriptional 
repression came almost in parallel to the discovery of HAT enzymes. The 
histone deacetylases are classified into three classes (Gray & Ekstrom, 2001). 
Class I contains HDAC 1-3, 8 and 11 which are related to the yeast Rpd 3 
histone deacetylases. Class II contains HDAC 4-7, 9 and 10 which are related 
to the yeast Hdal histone deacetylases (Shaowen et o/., 2004). Class III, is also 
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known as the Sir2 (silent information regulator) like deacetylases family, 
consists of 7 genes related to yeast Sir2 and have nicotinamide adenine 
dinucleotide (NAD)*-dependent deacetylase activity (Shaowen etal., 2004). 
1.4.7 Histone deacetylase inhibitors (IHDACi) 
Effective histone deacetylase inhibitors can cause hyperacetylation of 
nucieosomal histones and histone deacetylation repression (Robin & Douglas, 
1999), which affects cell growth, proliferation, differentiation, and/or 
apoptosis. HDACi can be divided into four major classes based on their 
chemical structures. Even though, all classes of HDACI promote acetylation, 
each individual HDACi has a different effect on the stimulation of 
differentiation and/or apoptosis (Boffa et al., 1978). Short-chain fatty acids, 
valporic acid and Sodium butyrate, non-specifically react with enzymes and 
inhibit deacetylation with millimolar concentration which is a relatively high 
dose (Boffa et al., 1978; Candido et al., 1978). It is important to note that only 
these two fatty acids have been approved, so far, for safe clinical use (Blaheta 
et al., 2002). The hydroxamate class of HDACi, including Trichostatin A (TSA), 
suberoylanilide hydroxamic acid (SAHA), SuberoyI bis-hydroxamic acid (SBHA), 
pyroxamide, and oxamflatin, inhibit deacetylation selectively and are effective 
at a lower concentration dose (in the micro-nano range) (Gore and Carducci, 
2002) . For example TSA and SAHA stimulate reversibly about 2% of specific 
gene promoters (Van Lint et al., 1996) and induce differentiation both in vitro 
and in vivo (Yoshida et al., 1990).The cyclic tetrapeptide class contains 
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Trapoxjn, apicidin, and depsipeptide (FR901228). Depsipeptide is a natural 
product. The trapoxins have been isolated from fungal metabolites as cyclic 
tetrapeptides and they irreversibly inhibit HDAC. Their inhibitory effects are 
obtained at nanomolar concentration. The last class of HDACi are comprised 
of synthesized benzamid derivatives MS-275 and CI-994; CI-994 has an 
effective suppressive activity on cancer cell proliferation. 
1.5 Anthracyclines and epigenetic components 
1.5.1 Interaction with DNA: Binding of sequence specific intercalators 
There is compelling evidence that cellular DNA is the primary target for 
these drugs. Quantitative microspectrofluorometry has been used to show 
that adrlamycin rapidly accumulates in the nuclei of living cells and is nearly 
completely bound to DNA (Gigli et ai, 1988). Flow cytometry has shown that 
daunomycin is intercalated into DNA within the cell (Belloc et al., 1992). 
Furthermore, the surface-enhanced Raman spectrum of adriamycin within 
the nuclei of erythroleukemia cancer cells was found to resemble that 
observed in vitro for the drug-DNA complex (Nabiev et al., 1991). Together 
with many other reports all this clearly suggests that anthracycline antitumor 
antibiotics are strongly associated with nuclear DNA in vivo. From a 
mechanistic point of view, drugs that interact with DNA can be divided into 
two broad categories: intercalating drugs and those that chemically bind to 
DNA. Anthracycline antibiotics are classified in the first group. Intercalators 
bind to DNA by inserting their planar chromophores between DNA bases. In 
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addition to stacking and hydrophobic interactions, the intercalation can be 
further stabilized by hydrogen bond formation in-between the bases of DNA, 
a situation where the sugar moieties are interacting with the central 
chromophores of the drug (Wang, 1993). The anthraquinone ring intercalates 
between DNA base pairs, with its long axis nearly perpendicular to the axis of 
the double helix. One of the rings acts as an anchor and stabilizes the complex 
through hydrogen bond interactions as the daunosamine sugar lies in the 
minor groove. The occurrence of a single positive charge on daunomycin 
contributes electrostatically to the binding. Binding of daunomycin and 
adriamycin to DNA has been extensively characterized. Equilibrium dialysis, 
absorption and fluorescence spectroscopy and phase partition methods have 
shown the occurrence of a negative cooperative binding isotherm pattern in 
the formation of the daunomycin-DNA (or adriamycin-DNA) complex 
(Barcelo' et ai, 1988). However, our results and those of others using the 
same technique have demonstrated the occurrence of positive cooperative 
binding isotherms (Graves & Krugh, 1983). These controversial results could 
be due to differences in the DNA sequence and/or experimental conditions 
used. The magnitude of the binding constant of daunomycin to DNA is 
strongly dependent on the base pair composition of DNA. Binding of 
daunomycin and adriamycin to DNA increases Tm of DNA melting point by 
sec as saturation of the potential binding sites is reached (Chaires et al., 
1982). Increase in Tm values of DNA is due to stabilization of DNA double 
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helix resulting from the intercalation of the drug and can be used to explain 
DNA and RNA synthesis inhibition, as well as the effects of these drugs. 
1.5.2 Interaction with the chromatin: unfolding transitions that lead to 
aggregation. 
It is obvious that a simple intercalation model for the interaction of the 
drugs with DNA is not enough to explain their overall mechanism of action in 
the cell. In the cell nucleus, DNA does not exist as a naked structure but is 
associated with a variety of proteins making a nucleoprotein complex called 
chromatin (van Holde, 1988). The mechanism of interaction and possible 
intracellular targets of antitumor drugs are often inferred from studies of the 
affinity of these drugs for free DNA in solution. Yet the tertiary structure and 
environment of DNA in the cell can significantly modulate these interactions. 
Equilibrium dialysis, hydrodynamic and electric dichroism techniques have 
been used to investigate the effects of anthracycline antibiotics on chromatin. 
Binding isotherms obtained from the interaction of daunomycin with 175 bp 
nucleosomes (depleted of histone HI) at several ionic strength conditions 
suggest a negative cooperative pattern and a strongly reduced binding 
relative to free DNA (Chaires et ai, 1983). It was shown that the affinity of 
daunomycin for different nucleohistone complexes is in the following order: 
DNA >175 bp H1/H5 depleted nucleosomes > nucleosome core particles 
(Chaires et ai, 1983). These results are in agreement with those observed for 
the interaction of daunomycin with chromatin containing either the full native 
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linker histones (HI and H5) or depleted of these histones (Chaires et ai, 
1996). Addition of daunomycin to 175 bp Hl-depleted nucleosomes or 146 bp 
nucleosome core particles stabilizes their low melting transition temperature, 
which corresponds to the regions of the nucleosomal DNA less tightly bound 
to the histone octamer at the flanking ends of the particle (Chaires et ai, 
1983). Comparative studies between Hl-depleted 175 bp nucleosomes and 
their constitutive DNA using circular dichroism and hydrodynamic studies 
have provided additional useful structural information. Binding of 
anthracyclines increases the ellipticity of the positive band at 275 nm in 
nucleosomes and to lesser extent in DNA. The relatively larger change 
observed with nucleosomes is most likely the result of DNA additionally 
becoming freed of the histone interaction constraints. Binding of the drug to 
the nucleosomal DNA is impeded by the core histone tails (Mir et ai, 2004). 
Once a critical amount of DNA has been unraveled, the nucleosome subunits 
start losing their stability and, as a result, the nucleoprotein complexes start 
aggregating in a process that is reminiscent of the nucleosome aggregation 
observed in vitro when nucleosomes are trimmed with micrococcal nuclease 
beyond 140 bp. By using a combination of absorption and fluorescence 
spectroscopy, thermal denaturation and equilibrium dialysis techniques 
(Zargar & Rabbani, 2002), it has been shown that similar to what is observed 
for the interactions with DNA, the binding of daunomycin to histone HI 
stabilizes the protein against thermal denaturation. This is in contrast to the 
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binding of adriamycin to HIVIGBl, which destabilizes the protein against 
thermal melting. Binding of daunomycin to nuclear nonhistone proteins 
within regulatory regions of the genome (for instance in the case of 
topoisomerases) can interfere with the synthesis of macromolecules essential 
for cell proliferation (Campiglio et al., 2003). Therefore, daunomycin may 
exert a dual effect on cell proliferation both regulating and modifying the 
template activity of DNA that would be required for the normal RNA synthesis 
and DNA repair. Mechanistically, such drugs may block the activity of 
processive enzyme complexes and/or interfere with the access of 
transactivating factors to DNA (Peterson & Tupy, 1994). Indeed anthracyclines 
have been shown to inhibit the activity of topoisomerases I and II (Lothstein 
et al., 2001) impairing the DNA repair and DNA replication activities of the 
cell. 
1.6 Cell membrane integrity vs cell death 
The immediate effect of exposing cells to hyper osmotic environment is a 
fast increase of osmotic pressure in the cell interior. It results from a rapid 
outflow of water and a slower entry of permeant solutes into the cell interior 
until a stationary state is reached, i.e. when extracellular and intracellular 
osmotic pressures are equal (Gervais & Beney, 2001). As a result, the volume 
of the cell decreases within seconds (Berner & Gervais, 1993). This passive 
osmotic response of cells involves the dehydration of the cell components 
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and the shrinkage of the plasma membrane (Adya et ai, 2006). In the same 
way, a return to the initial osmotic pressure induces a cell volume increase 
(Morris et ai, 1986) and rehydration of the cell components. As a 
consequence, the integrity and function of the plasma membrane are 
affected by osmotic pressure variations in the cellular environment. The 
cytoplasmic membrane is a chemiosmotic barrier that provides the interface 
between the organism and its external environment. A transmembrane 
electrochemical potential (negative inside) across this phospholipid bilayer 
plays a pivotal role in the control of solute exchange. Increased plasma 
membrane permeability during dehydration or rehydration has been 
proposed as the main cause of cell death. In fact, increases and decreases in 
osmotic pressure induce the leakage of nucleotides, ions, and other soluble 
cell components into the surrounding medium (Rapoport et ai, 1995). The 
highly dynamic lipid bilayer of the plasma membrane is known to undergo 
phase transitions during dehydration (Laroche et ai, 2005) and rehydration 
(Crowe et ai, 1989). On one hand, the occurrence of a phase separation state 
resulting from the phase transition of some phospholipids in the membrane 
may be the cause of membrane rupture or changes in permeability, as 
proposed by Laroche and Gervais (2003). On the other hand, some authors 
suggest that the formation of endovesicles during dehydration leads to 
plasma membrane lysis during osmotic expansion at rehydration (Uedaira et 
ai, 2001), ultimately leading to cell death. 
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1.7 Anthracyclines and cell cycle: Role of DNA damage and p53 
Doxorubiein, as many other genotoxic agents, activates p53-DNA binding. 
On the basis of the crucial role of p53 in the execution of some forms of 
apoptosis, it has been proposed that p53 could play an important function in 
anthracydine cytotoxicity. Preclinical and clinical studies support this concept 
(Ruiz-Ruiz et a/., 2003), but negative reports have also appeared (Gariboldi et 
al., 2003). Uncertainties about the role of p53 in anthracycline-induced 
apoptosis may be attributed to various factors like heterogeneity of the 
tumors examined or of the methods used for assessing p53 status and tumor 
response. 
An additional factor of consideration pertains to the role of p53 in 
regulating cell cycle transition in DOX-treated cells. In fact, DOX-dependent 
p53 activation contributes to the induction of the WAFl/CIPl p21 gene 
product, a strong inhibitor of cyclin-dependent kinases involved in Gi to S 
transition. Whereas this mechanism has been proposed to contribute to Gi 
arrest of p53-proficient cells, it has also been suggested that WAFl expression 
might protect cells from DOX because the Gi block facilitates DNA repair 
before the cells undergo DNA replication. It is in keeping with this concept 
that constitutively high levels of WAFl/CIPl protein were shown to associate 
with chemoresistance in acute myelogenous leukemia (Zhang et al., 1995). On 
the other hand, the ability of p53-deficient cells to progress through the S 
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phase may be a favorable event, since the expression of the a-isoform of 
topoisomerase II is increased during DNA synthesis. Further complexity is 
introduced by recent data showing that p53 might be important not only in 
connecting DNA damage to downstream execution of apoptosis but also in 
determining the net levels of DNA strand breaks induced by DOX (Dunkern et 
al., 2003). Studies of p53-proficient versus -deficient cells showed comparable 
levels of expression and activity of topoisomerase II in the two cell types, yet 
p53-proficient cells exhibited more DNA damage (Dunkern et al., 2003). One 
possibility is that p53 interacts with topoisomerase II and inhibits its ligase 
function, eventually amplifying the net levels of formation of irreversible 
strand breaks (Dunkern et al., 2003). All such issues clearly require 
refinements, since many human tumors show p53 mutations that bear 
important implications for chemotherapy. 
Uncertainties about the complex interplay between p53 and 
anthracycline-induced apoptosis are also due to the presence of alternative 
networks that are not bound to an inhibition of topoisomerase II nor do they 
always require functional p53, and therefore extend beyond the tentative list 
of mechanisms provided by Gewirtz (1999) in his thoughtful analysis. 
Moreover, it is becoming increasingly evident that anthracyclines can directly 
release cytochrome c from mitochondria, thereby inducing apoptosis 
regardless of DNA damage or signaling pathways or p53 status (Green & 
Leeuwenburgh, 2002). Needless to say, these are just a few of the plethora of 
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mechanisms that have been characterized in recent years in relation to the 
mode of action of anthracyclines. Because authoritative commentaries of 
these mechanisms have already appeared (Laurent & Jaffrezou, 2001; Perego 
et al., 2001; Kim et al., 2002), we have focus on the most recent advances in 
DNA damage by anthracyclines, with particular reference to the discovery of 
novel mechanisms for the action of anthracyclines. 
1.8 Objective of the Research 
The overall objective of this research was to elucidate the mode and 
mechanism of anthracyclines interaction with chromatin (core Histones and 
DNA), its affect on the pattern and level of histone acetylation and determine 
its response on cellular transcription. 
We started our work in three directions to achieve the set goal: 
a) We evaluate the interaction of epirubicin (EPI) and mitoxantrone (MTX) 
histones and their state of acetylation. To study effect of these drugs on the 
enzymatic machinery involved in the process was also in our study frame. 
b) We also investigated the interaction of above stated drugs with the naked 
DNA, its base specificity and the effect of drug on transcription factor 
assembly could provide us the better understanding of its pharmacological 
action. 
c) It is also of interest to assess the effects of anthracyclines on cellular 
components, cell integrity and cell cycle necessary for the normal biochemical 
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processes (like replication, division and most important with the 
transcription) of cell proliferation and multiplication. 
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2.1 Materials 
2.1.1 Proteins 
Calf thymus histone core was purchased from Sigma Inc. and histone 
H3 was purchased from Roche Applied Science. Commercial preparations of 
histones were used as such throughout the biophysical studies. 
2.1.2 Drugs/Ligands 
Anthracydines antibiotics, epirubicin (EPI) and mitoxantrone (MTX) 
were purchased from sigma-aldrich chemicals. 
2.1.3 Reagents used in protein estimation 
Analytical grade samples of sodium potassium tartarate, sodium 
carbonate and copper sulphate were obtained from Qualigens. Folin-phenol 
reagent was prepared according to the standard procedure (Folin & Ciocalteu, 
1927). Copper reagent was prepared by mixing 1 volume of 4% (w/v) sodium 
potassium tartarate with 100 volumes of 4% (w/v) sodium carbonate and 
finally adding 1 volume of 2% (w/v) copper sulphate. 
2.1.4 Reagent used In polyacrylamlde electrophoresis 
Acrylamide and N, N'- methylene bisacrylamide were purchased from 
Sisco Research Laboratories Pvt. Ltd., Mumbai India. Glycine, 
dimethyldichlorosilane, coomassie brilliant blue R-250 and sodium 
dodecylsulfate (SDS) were obtained from Sigma Chemical Company, St. Louis, 
USA. Ammonium persulfate, glycerol, glacial acetic acid and methol were 
procured from Qualigens Fine Chemicals, Mumbai, India. TEIVIED was the 
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product of fluka AG, Switzerland. 2-mercaptoethanol was purchased from E. 
Merck, Darmstadt, Germany. Bromophenol blue was the product of B.D.H., 
Poole England. 
2.1.5 Reagents used in agarose gel electrophoresis 
Agarose, ethldlum bromide, bromophenol blue were obtained from 
Sisco Research Laboratories Pvt. Ltd. India. Sucrose was procured from 
Qualigens Fine Chemicals, Mumbai, India. Trizma base (Tris [hydroxymethyl] 
aminomethane) was obtained from Sigma Chemical Co., St. Louis, USA. 
2.1.6 Miscellaneous 
Penicillin G, streptomycin and L-glutamine were from sigma-aldrich 
chemicals, USA. DMEM and fetal bovine serum were obtained from clontech 
lab., USA. Millipore filters (pore sizes 0.25 and 0.45m) were purchased from 
Millipore Pvt. Ltd., Bangalore, India. Watman filters papers (No.l) were the 
product of Watman International Ltd., Maidstone, England. Parafilm 'M' was 
obtained from Qualigens Fine Chemicals, Mumbai, India. Aluminium foil was 
obtained from S.R. Foil Ltd. New Delhi, India. Double distilled water was used 
throughout these studies. 
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2.2 Methods 
2.2.1 pH measurements 
pH measurements were carried out on cyber scan digital pH meter 
model 510 attached with a thermal probe .The pH meter was routinely 
calibrated at room temperature with standard buffers. The pH was adjusted 
using IN hydrochloric acid and IN sodium hydroxide with constant stirring. 
2.2.2 Determination of protein concentration 
The protein concentration was determined following absorbance 
measured at 278 nm the shimadzu extinction either spectrophotometrically, 
model 1602 or by the method of Lowry etal. (1951). 
(a) Spectrophotometric method 
Protein concentration was determined following absorbance 
measurement at 278 nm on the shimadzu UV-Visible spectrophotometer, 
model 1602 and using the value of specific extinction coefficient {Ei%lcm) as 
for protein (Pace etal., 1999) 
(b) IVIethod of Lowry et al. (1951) 
Increasing volumes of the stock protein solution (500 |ig/ml) in the 
range of 0.1-1.0 ml were taken in the different test tubes and the volume in 
each tube was made to 1.0 ml with 10 mM sodium phosphate buffer, pH 7.0. 
Then, 5.0 ml of freshly prepared copper reagent was added to ail the tubes 
and the contents were mixed well. After 10 min of incubation at room 
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Figure 2.1 Calibration curve for the estimation of protein concentration by the 
method of Lowry et a! (1951) using BSA as standard. 
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temperature, 1.0 ml diluted Folin-phenol reagent was added and vortexed. 
The tubes were incubated for 30 min at room temperature and the colour 
intensity was read at 700 nm against a reagent blank. A calibration curve, was 
thus obtained, between absorbance at 700 nm and amount of protein yielded 
the following straight line equation (Fig. 2.1) 
(Absorbance) yoonm = 1-4 x 10'^  (protein concentration ng/ml) - 0.05 
2.2.3 Quantitative analysis of DNA in solution 
Spectrophotometric estimation of DNA was carried out according to the 
method of Schneider (1957) by using diphenylamine reagent. 
(a) Diphenylamine reagent 
1.0 gram of diphenylamine was accurately weighed and dissolved in 
100 ml of glacial acetic acid. To this 2.75 ml of concentrated sulfuric acid was 
added and mixed thoroughly. The diphenylamine reagent was prepared fresh 
at the time of experiment. 
(b) Estimation of DNA by DPA method 
A calibration curve for DNA estimation was prepared as follows: 
Aliquots were taken out in different test tubes from standard solution of calf 
thymus DNA (500 ng/ml) in order to achieve a concentration range of 25-300 
HM. Volume in each test tube was made up to 2.0 ml HEPES buffer. To each 
test tube 4.0 ml of freshly prepared DPA solution was added. A parallel 
control was also prepared as reagent blank. All the tubes containing the 
reaction mixture were then heated in boiling water bath for 30 minutes, until 
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a blue colour develops. The absorbance was read at 600 nm against the 
reagent blank on double beam spectrophotometer, using quartz cuvettes of 
1.0 cm path length. The graph between absorbance at 600 nm and the 
concentration of DNA (Fig. 2.2) yielded the following straight-line equation. 
(Absorbance)6oonm = {1-164 x 10'^ ) MM of DNA - 0.009 
Above concentration was used through out the experiments to determine the 
concentration of acid soluble nucleotides. 
2.2.4 Determination of minimum inhibitory concentration (MIC) of drugs 
against yeast 
The strain of yeast was inoculated in the YPD media and grown to 
stationary phase for 24 h at 30 "C up to 10^- 10^ CFU/ml. 50 \i\ of overnight 
grown culture diluted to 10^-10^ CFU/ml was inoculated into fresh YPD (SOpil) 
containing varying concentration, serially diluted tested drugs. The MIC was 
defined as the minimum concentration of the drugs limiting turbidity to <0.05 
absorbance unit at 700 nm. 
2.2.5 Yeast two-hybrid system 
We have used the GAL-4 based yeast two hybrid system in the 
experiments (Sengupta ef o/., 1996). Briefly, competent cells were prepared 
and the pellet was resuspended in 1 mL of LiOAc (0.1 M). In order to do the 
transformation into host yeast cells, appropriate fusion constructs (10 \ig) 
were mixed with 4 ng of carrier DNA in a microcentrifuge tube. 
43 
chapter 2 
Transformation was done using appropriate plasmids and the cells were 
finally resuspended into 100 \iL of water and plated on YPD. The plates were 
Icept at 30 'C for 3 days and 10 individual colonies from each YPD plate were 
then streaked on media devoid of Leucine, Uracil and Histidine, containing 
different concentrations of 3-amino-l, 2,4-triazole (3-AT) varying from 0 mM 
to 50 mM and the plates were used to streak these colonies and were kept 
for 3 days at 30'C. 
2.2.6 Culturing of HEK 293 cell line 
Culture conditions vary widely for each cell type, and variation of 
conditions for a particular cell type can result in different phenotypes being 
expressed. Aside from temperature and gas mixture, the most commonly 
varied factor in culture systems is the growth medium. Recipes for growth 
media can vary in pH, glucose concentration, growth factors, and the 
presence of other nutrients. HEK 293 cells were thawed rapidly by briefly 
immersing the vial in a 37'C water bath (e.g., 2-3 min with constant 
agitation). Upon thawing outside of the vial was wiped with 70% EtOH and 
Content was then transfer to a T25 flask. DMEM media (4 ml media 
supplemented with 100 units/ml penicillin G sodium, 100 mg/mi 
streptomycin, 4 mM L-glutamine, and 10% fetal bovine serum) was added 
gently by swirling the flask to distribute cells evenly over the growth surface. 
The culture was kept under the condition of optimum temperature (syc) and 
at 5% CO2, humidified incubator. Cells were examined under microscope 
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before use. Healthy cells display a flat morphology and adhere well to the 
plate. Splitting of cells were done every third day, when they reach 70-80% 
confluency. As a general rule, HEK 293 cells should not be allowed to become 
confluent nor should they be seeded too sparsely (We plated cells at a density 
of 100 cells/mm^). For cell slitting, the medium was removed and cells were 
washed the cells once with prewarmed sterile PBS (containing no Ca^ * or 
Mg^*). Trypsin-EDTA solution (1-2 ml) was added for 1-2 min, until cells get 
detached. To stop trypsinization, 5-10 ml of growth medium was added and 
then cells were resuspended gently. Desired number, of counted cells were 
transferred to a new culture flask or plate containing an appropriate volume 
of growth medium. Gently rock or swirl the plate or flask to evenly distribute 
the cells. These cells were used for the desired experiment. 
2.2.7 Sodium dodecyi sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) 
Equal amount of 2X SDS Laemmli buffer and protein sample were 
mixed and boiled for 5 min at SO'C. Protein bands were analyzed by SDS-
PAGE. The 12% resolving gel was made with bis-acrylamide, 1.5 M Tris-HCL 
(pH 8.8), 10% SDS (Fisher Scientific), 10% Ammonium persulphate, and 0.05% 
TEMED (Bio-Rad Laboratories Ltd, Canada). The 4% stacking gel was made of 
using all of the above, but the Tris-HCL buffer was 0.5 M with pH 6.8. Mini-
Protein® II gel apparatus (Bio-Rad Laboratories Ltd, Canada) was used to run 
the gels followed by the staining with Coomassie blue G-250 (J. T. Chemical 
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Co, NJ, USA). Furthermore, similar gels were transferred directly to PVDF 
membranes in order to detect the bands with specific antibodies. 
2.2.8 Antibody detection 
An ECL plus western blot analysis detection kit was used according to 
Manufacturer's protocol (Amersham Biosciences Canada, GE Healthcare Bio-
Sciences IncQuebec, Canada) to discern bound antibody. Detection solution 
A and B were mixed in a ratio of 40:1, then, blots were incubated for 5 
minutes, and detected using X-ray film (Fisher Scientific Company, Ottawa, 
ON, Canada). The film was exposed for 10 seconds, depending on the 
intensity of the band, the second film was exposed either for a longer or 
shorter period of time. Equal loading of each gel was verified by comparing 
with the immunoblotting of loading control and negative control without 
antibody. 
2.2.9 Preparation of agarose gel 
Agarose gel of 0.8 % compositions was prepared as follows: 0.8 g of 
agarose was weighed and mixed with 100 ml of Ix (40 mM) TAE buffer, pH-
7.8. The mixture was then heated until the agarose dissolved completely. The 
clear solution obtained was then poured in the polymerization chamber of 
the horizontal electrophoresis assembly. The comb was placed at one end of 
the chamber to cast the wells in the gel. it was polymerized at room 
temperature for 30 min. 
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2.2.10 Statistical analysis 
All experiments were repeated at least three times and each 
experiment was performed at least in duplicate. The data were expressed as 
means ± SD (standard deviation), wherever required. Statistical analysis was 
performed by using Student's t test. The criterion for statistical significance 
was p<0.05. The data obtained were analyzed statistically using SPSSv.lO 
software (SPSS Inc. Headquarters, Chicago, IL). A comparison between the 
groups of interest was performed by descriptive analysis. 
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3.1 Introduction 
Epirubicin (EPI) and mitoxantrone (MTX), among the anthracydine 
antibiotic are the most common antitumor drugs used in clinical oncology, 
especially in the treatment of acute carcinoma. Anthracydine cytotoxicity is 
generally believed to be the result of drug-induced DNA damage. Though, its 
mode of action has been examined extensively over the past 20 years. 
Different studies have cited the interaction of the inherently reactive drug 
with cell membranes, DNA, proteins, metal ions, and molecular oxygen, 
leading to an apparently complex interplay of the mechanism of antitumor 
action, the major determinants of which may differ according to the 
properties of target cancer cells (Myers et al., 1988). How and why such 
events should bring about cell death remains unclear, especially when one 
considers them not to be a prerequisite for anthracydines antitumor activity 
(Tritton, 1991; Ross et al., 1979; Zwelling et al., 1982). Although the 
reactivities of anthracydines with a range of cellular targets are well known, 
the specific cellular mechanisms involved and the ultimate cause of tumor cell 
death are still to be elucidated. Hence, the exploration and understanding of 
the process of their action has forced a reconsideration of the mechanisms 
whereby cells respond to anthracydines. There is compelling evidence that 
cellular DNA is the primary target for this drug. It is obvious that a simple 
intercalation model for the interaction of the drug with DNA is not enough to 
explain their overall mechanism of action in the cell. In the cell nucleus, DNA 
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does not exist as a naked structure but is associated with a variety of proteins 
mal<ing a nucleoprotein complex called chromatin (van Holde, 1988). 
Interestingly, transcription in eukaryotic cells is influenced by the chromatin 
structure within which DNA is tightly packed (Strahl & Allis, 2000). The 
nucleosome is the basic unit of chromatin and consists of 146 base pairs of 
DNA wrapped around a histone octamer. The histone tails are modified by 
acetylation, phosphorylation, methylation and ubiquitination (Luger et al., 
1997; Luger et al., 1998). Compared with methylation and phosphorylation, 
the acetylation of core histones is probably the best understood type of 
modification (Gray & The, 2001; Gregory et al., 2001). Acetylation of histone 
tails correlates with transcriptional activity in many genes. 
Henceforth, this opens new vistas for studying the affect of these 
drugs on histone acetylation. One possible physiological action in tumor cells 
involves the altered pattern of histone modification, more specifically histone 
acetylation which is supposed to play a crucial role in cellular proliferation 
and differentiation. Covalent attachment of the drug chromophore to specific 
DNA consensus sequences required for recognition by DNA-binding proteins 
or directly to proteins or to the enzymatic machinery involved in the process 
may lead to altered levels and modes of action of these drugs. 
The quantitative binding of EPI and MTX with histone H3 and their 
possible role in histone acetylation has not yet been reported. Hence, herein 
we elucidate the interaction of most recommended anthracycline EPI and 
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MTX (only anthracycline approved by FDA) with the histone octamer, their 
binding was characterized in detail with histone H3, which is among the most 
putative histone to be acetylated. In view of the above background we 
initiated our study to characterize (i) the extent and nature of interaction of 
EPI and MTX with histones. (ii) Binding affinity and thermodynamic 
parameters for this interaction, (iii) Drug binding site and mode of binding 
was also evaluated. We further study the effect of these drugs on the 
enzymatic machinery involved in the process of histone acetylation and the 
resultant perturbation on the acetylation dynamics in the cell. 
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3.2 Experimental overview 
3.2.1 IVIateriais 
Calf thymus histone octamer was purchased from Sigma Inc. and histone H3 
was purchased from Roche Applied Science. The histones were reconstituted 
in 10 mM phosphate buffer of pH 7.4. The purity of the proteins was checked 
on 15 % SDS-polyacrylamide gel electrophoresis as described by Lammeli 
(1970). The protein concentration was determined according to Lowry et al 
(1951) using bovine serum albumin as a standard. Epirubicin (EPI) and 
IVIitoxantrone (MTX) were purchased from sigma-aldrich chemicals and their 
respective stock solutions were prepared in water. Dilutions of the drug 
stocks in the appropriate buffer were prepared immediately before use. Anti-
acetyl histone H3 K9/K14 were purchased from Upstate Biotechnology, anti-
C23 and anti-histone H3 antibodies from Santa Cruz Biotechnology. 
Trichostatin (TSA) was purchased from Sigma. 
3.2.2 Interaction of drug with histones 
To obtain the correct time of incubation, the purified core histone were 
incubated with various concentrations of drugs and histone H3 after different 
time intervals, aliquots were taken for further studies. Free drugs and 
histones were prepared in the same buffer and incubated along with the 
drug-histone samples under the same conditions and used as a control where 
needed. 
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3.2.3 Circular dichroism (CD) 
Circular dichroism (CD) measurements of histone core in presence and 
absence of drugs was performed in the far-UV (200-250 nm) region on a 
Jasco-J820 spectropolarimeter coupled to a microcomputer using a quartz cell 
of 0.1 cm. All the spectra were recorded at 298K and the temperature was 
maintained constant by a thermostatically controlled Neslab RTE-110 
circulating water bath. The molar ratio of histones to drug concentration was 
1:0,1:2 and 1:4, for CD spectra. 
3.2.4 Absorption spectroscopy 
The UV measurements of core histones were recorded on a Shimadzu 
double beam spectrophotometer model-UV 1700 using a cuvette of 1 cm 
path length. Absorbance value of protein in the presence and absence of the 
drugs were made in the range of 250-300 nm and protein concentration was 
fixed to 12 nM while the drug concentration was varied from 12 to 60 \xM 
3.2.5 iVlolecular modeling study 
Molecular docking simulations of Histone octamer interactions with 
the drugs were performed with GOLDvS.l.l program (Jones et al., 1995). The 
crystal structure of histone octamer was obtained from the brookhaven 
protein data bank (PDB). The two dimentional (2D) structure of drugs were 
retrieved from Pubchem (pubchem.ncbi.nlm.nih.gov). 2D to three 
dimensional (3D) conversion was done with CORINA (2001; www.mol-net.de). 
The structure of histone was protonated in Insight II (www.accelrys.com). 
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Genetic algorithm was implemented in G0LDv3.1.1 that was applied to 
calculate the possible conformations of the drug that binds to the protein. 
The genetic algorithm parameters used are: Population size-100; Number of 
lslands-5; Niche size-2; Selection pressure-1.1; Migrate-2; Number of 
operators-100,000; Mutate-95; Crossover-95. During docking process, a 
maximum of 10 different conformations were considered for the drug. The 
conformer with the lowest binding free energy was used for further analysis. 
The binding energy of docked complexes was calculated using X-Score (Wang 
et al., 2002). The residues involved in hydrogen bonding and hydrophobic 
interactions were calculated using Getneares, which is a tool available with 
DOCKvS.l.l (Kuntz et al., 1982). 
3.2.6 Fluorescence spectroscopy 
Fluorescence measurements were made on a Luminiscence 
spectrometer, model LS55 (Perkin Elmer). The fluorescence quenching of 
histone intrinsic fluorescence at increasing molar ratios of the drugs to 
protein was recorded in the wavelength range 290-350 nm after exciting the 
protein solution at 278 nm, using 3nm/3nm as slit widths. The protein 
concentration was fixed at 3.0 x 10'^  M and the drug concentration was varied 
from 3.0 to 34.0 x 10'^  M. To evaluate the effect of temperature at drug-
histone binding, fluorescence was recorded at four different temperatures i.e. 
298, 301, 306 and 310 K. The instrument was thermostatically controlled by a 
Neslab RTE-110 circulating water bath. 
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3.2.7 Energy transfer between the drugs and the protein 
The absorption spectrum of drugs (3.0 x 10'^  M) was recorded in the 
range of 290-350 nm. The emission spectrum of histone (3.0 x 10'^  M) at \ex 
=278 nm was also recorded in the range of 290-350 nm. The overlap of the 
UV absorption spectrum of the drugs with the fluorescence emission 
spectrum of the protein was used to determine the energy transfer as per the 
Forster's theory (F "orster & Sinanoglu, 1996) 
3.2.8 Cell culture and treatment conditions 
Human embryonic kidney cell line 293 (HEK293) was maintained in 
DMEM (Biological industries Ltd.), supplemented with 10% bovine calf serum, 
100 units/ml penicillin, and 100 ng/ml streptomycin (Invitrogen). They were 
cultured at 310K in a humidified, 5% CO2 incubator at an initial density of 5 x 
10^ cells /ml in DMEM culture medium. The cells were always incubated in 
serum-free conditions overnight prior to treatment. The cells were then 
treated with different concentration of drugs and incubated for eight hours. 
3.2.9 Nuclear extract preparation 
Extracts were prepared as described by Schreiber et al. (1989). Cells (5 
xlO^) with 70% confluency, were washed twice with ice-cold PBS and 
resuspended in 10 mM HEPES (pH 7.8), 10 mM KCI, 0.1 mM EDTA, 0.1 mM 
EGTA, 1 mM DTT, 1 mM phenylmethylsulfonyl fluoride, 2 mM pepstatin A, 0.6 
mM leupeptin, 1 mg/mi aprotinin, and 0.6% NP40. The nuclei pellet was 
recovered after centrifugation at 1200 X g and resuspended in 20 mM HEPES 
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(pH 7.9), 0.4 M NaCi, 1 mM EDTA, and 1 mM EGTA. Aliquots were then 
incubated at 277K for 30 min, centrifuged at 21,000 X g, and supernatant 
containing nuclear proteins was removed. Protein concentratioo was 
^ K ^ f ^ - ^-.-.-rt, 
determined according to Lowry et al. (1951). **,' ~ P ^ \ 9l \ , 
3.2.10 HAT activity assay ^ ^ ; ' , / 
V. • - - <y 
Histone acetyltransferase (HAT) activity was determined usiiiig'"the' -' 
coiorimetric HAT activity assay Icit (BioVision Inc.). Prepared nuclear extract 
(50 ng) was dispensed in 40 \i\ of water for each assay in 96-well plate. For 
background reading, add 40 ^1 water instead of the sample. For positive 
control, add 5 nl of the active HAT (P300/CAF) in 35 pil of water. The test 
samples were treated with different concentrations of the drugs (0.1 to 5.0 
HM). Then, add 50 \x\ of 2X HAT assay buffer, 10 ^1 of HAT substrates and 5 \i\ 
of NADH generating enzyme. The reaction got initiated by adding peptide 
substrate to the nuclear lysate, containing active HATs, and incubated at 310K 
for 2 hours. Enzyme activity was measured using a calorimetric plate reader 
(Qualigens, India). The cell lysate was boiled for 15 min and taken as negative 
control. Positive control provided was used for analysis. Results represented 
as mean ± SD of three independent experiments. 
3.2.11 HDAC activity assay 
Effect on histone deacetylase (HDAC) activity was determined using the 
coiorimetric HDAC activity/ inhibition assay kit (Epigentek Group Inc.). Add 50 
\i\ of biotinylated HDAC substrate to the 96 well microtitre plate [aspirate and 
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wash the wells with 150 pil of lOX wash buffer after 45 min]. Nuclear extract 
(50 ng) in total volume of 30 \i\ was added in the tested wells, which were 
treated with different concentration of drugs. Additional negative control 
includes the sample incubated without the nuclear extract. TSA at 1 \M 
concentration served as the positive control. The incubation of reaction 
mixture at 298 K for 30 min allowed deacetylation to take place. After 30 min, 
the wells were washed with the wash buffer and developer was added for 5 
min. On development of the blue color in the standard well, the stop solution 
was added to the assay plate and absorbance was read at 450 nm. Percent 
inhibition was calculated with reference to untreated control sample. 
3.2.12 Immunoblots 
The nuclear extracts of cells treated with different concentrations of 
drugs with their respective controls were estimated for the optimal amount 
of protein. Equal amounts of proteins were separated by SDS-PAGE at 120V. A 
molecular weight marker was loaded in all gels. After SDS-PAGE, the proteins 
were transferred to nitrocellulose membranes. The membranes were blocked 
with 5% milk in TBS-Tween 20 solution for 1 h, followed by overnight 
incubation with primary antibody (anti-Acety K9 & K14) at 4 "C and finally 
incubated for 1 h with secondary antibody conjugated with horseradish 
peroxidase (sigma-aldrich). Detection was done by ECL-Western Lightning 
Chemiiuminescence reagent (Amersham Pharmacia). The blots were stripped 
in 10 % SDS buffer and re-probed for histone H3 and C23 to normalize for 
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protein loading in each lane. Gels incubated without the antibodies were used 
as negative controls. 
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3.3 Results and Discussion 
3.3.1 Circular dichroism (CD) analysis 
To elucidate the effect of the drugs on the core histone, we employed 
this technique to provide an insight of the structural alteration in protein on 
drug treatment. In this work, the molar ratios of 1:0,1:2,1:4 and 1:6 for core 
histones: drugs were used for the CD measurements. The CD spectra of 
protein in the absence (curve a) and presence (curve b-d) of the drugs are 
shown in Figure 3.1 (A & B). The CD spectra of core histones exhibited one 
prominent negative bands in the UV region around 208 nm and a small peak 
near 220 (Fig.3.1, A & B; curve a), characteristic of an induced a-helical 
structure of histones (Larissa et al., 2004). The reasonable explanation is that 
the negative peak between 208 and 209 nm is supposed to be the outcome of 
n->Ti* transfer for the peptide bond of a-helices (Miles et al., 1962). First 
titration of the drugs resulted in the increment of the negative peak (curve b) 
which further increased on addition of the drugs (curve c-d). The results 
inferred drastic variation in the protein structural content, as the drug blank 
was used in case of both the drugs to normalize their signals. The alteration in 
ellipticity is suggestive of the perturbation of the helical content, illustrating 
the perturbation of the structural content of core histones on drug 
interaction. 
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200 220 240 260 
Wavelength [nm] 
Figure 3,1(A) The Far UV-CD spectra of core histories native (a); native+ 6.0 x 
lO'^M EPi (b), native+12.0 x lO'^M EP! (c) and native+24.0 x lO'^M EP!, (d). 
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200 220 240 260 
Wavelength [nm] 
280 300 
Figure 3.1(B) The Far UV-CD spectra of core histones native (a); native+ 6.0 x 
10"^M MTX (b); natJve+12.0 x 10"^M MTX (c) and natiye+24.0 x 10"^M MTX, (d). 
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3.3.2 Absorption spectroscopy 
UV-Vis absorption studies were performed to further characterize the 
interaction of core histones with the drugs. The UV absorbance showed an 
increase with the increase in drug concentration (Fig.3.2, A & B). Also, a 
distinct blue-shift in peak was observed on interaction of protein with EPI as 
compared to MTX. These two changes were indicative of a complex formation 
between the protein and the drugs (Hu et o/., 2004; Cui et al., 2004). 
3.3.3 Molecular modeling of drug binding with core histones 
In solution experiments may be more closely represent physiological 
conditions but it is difficult to determine the location of the binding sites in 
them. The G0LDv3.1.1 program was chosen to examine the binding of EPI and 
MTX at the active site of core histone. The best docked conformation of drug-
protein complex is shown in figure 3.3 (A & B). Best energy results has placed 
the drugs near histone H3 sharing the binding site with DNA. The binding site 
is situated near the N-terminal lysine 9/K9 and 14/K14. The interaction 
between the drugs and the protein is depicted in the lig plot (Fig. 3.4, A & B), 
which depicts the involvement of hydrophobic contacts and hydrogen 
bonding in the drug-protein complexes. The hydrogen bonding acts as an 
"anchor", intensely determining the 3D space position of EPI and MTX in the 
binding pocket and facilitating the hydrophobic interactions of the 
dihydroxyanthraquinone rings with the side chain of protein. It is worth 
mentioning that the docking 
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Figure 3.2(A) Absorbance spectra of EP!, core Histone and core Histone-EP! 
system. Protein concentration was 12 x 10 M (a). EP! concentration for drug-
protein system was at 12 x lO'^M (b), 24 x lO^^M (c), 36 x 10"^M (d), 48 x lO'^M 
(e) and 60 x lO'^M (f). A. concentration of 12 xlO"^ M EP! (x) was used for drug 
aione. 
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Figure 3.2(B^ A.bsorbance spectra of MTX, Histone and Histone—MTX system. 
Protein concentration was 12 x 10 iV! (a). MTX concentration for dru'^ — 
protein system was at 12 x lO'^M (b), 24 x 10^iV! (c), 36 x lO'^M (d), 48 x lO'^M 
(e) and 60 x lO^M (f). A concentration of 12 xlO^ M MTX (x) was used for 
Hnip alnnp 
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Figure 3.3 Computational model of EPl (A) and MTX (B) docked to histone 
core. Drugs represented as orange colour stick model and pink colour depicts 
strongest interaction between the drug and the protein. Histone depicted in 
green space filled model. The image was made using Pymol 
(pymol.sourceforge.net). 
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^m 
Figure 3.4(A) Lig plot for representation of the molecular interaction between 
the EPI and the core histone. The dotted lines, depicts the hydrogen bonding 
and the outward ticks represents the hydrophobic contacts. 
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His39(A)F 
Lys 37(A) 
Pro38(A)t 
Figure 3.4(B) Lig plot for representation of the molecular interaction between 
the IVITX and the core histone. The dotted lines, depicts the hydrogen bonding 
and the outward ticks represents the hydrophobic contacts. 
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procedure placed the drug molecules within the vicinity of N-terminal lysines 
(K9 & K14), implicating its interference in histone modification assisted 
regulation. 
3.3.4 Histone (H3) binding with the drugs 
Above results were suggestive of the interaction of EPI and MTX with the core 
histones and docking placed them at histone H3. As histone H3 are 
dynamically involved in histone modification and regulate the cellular 
transcription (Fuks F, 2005). Hence, we further evaluate the interaction of 
these drugs specifically with histone H3. 
The intrinsic fluorescence of histone MS with increasing concentration of 
the drugs was recorded in the range of 290-350 nm. The shift of the emission 
maximum wavelength from 308 to 304 and 308 nm was observed for EPI and 
MTX, respectively (Fig. 3.5, A & B). This implies the changed solvent 
accessibility of the protein induced on drug binding in the vicinity of aromatic 
fluorophore. It can be seen that a higher excess of these drugs led to more 
effective quenching of the chromophore molecule fluorescence. The 
quenching of the protein fluorescence clearly indicated that the binding of the 
drug to protein has changed the microenvironment of fluorophores. 
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310 320 330 
Wavelength [nm] 
340 350 360 
Figure 3.5(A) Effect of EP! on fluorescence spectrum of Histone H3 {T - 298 K, 
pH7.40, Xex - 280 nm). a-i , [Protein] - 3.0 • 10 ^ M, [Drug] ^ 0.0, 3.0, 6.0, 9.0, 
12.0, 15.0, 18.0, 21.0 and 24.0 x lO'^M, respectively. Curve x shovvs the 
emission spectrum of EPI alone. 
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310 320 330 
Wavelength [nm] 
Figure 3.5(B) Effect of MTX on fluorescence spectrum of Histone H3 (T - 298 
K, pH7.40, \ex = 280 nm). a-i, [Protein] = 3.0 • 10 ^  M, [Drug] = 0.0, 3.0, 6.0, 
9.0, 12.0, 15.0, 18.0, 21.0 and 24.0 x 10 ^ M, respectively. Curve x shows the 
emission spectrum of MTX alone. 
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3.3.4.1 Analysis of binding 
To further elaborate the fluorescence quenching mechanism the 
Stern-Volmer equation was used for data analysis: 
Fo/F=l+Ksv[Q] (3) 
where Fo and F are the steady-state fluorescence intensities in the absence 
and presence of quencher, respectively. Ksv the Stern-Volmer quenching 
constant and [Q] is the concentration of quenchers (EPI & IVITX). However, the 
Stern-Volmer curve showed an inclination toward y axis at higher drug 
concentrations (Fig. 3.6, A & B). This type of plot does not clearly distinguish 
between the type of quenching procedure (static or dynamic). Hence, the 
procedure of quenching was resolved from the values of bimolecular 
quenching rate constants, Kq, which are evaluated using the equation: 
Kq = KsWTQ (4) 
where TQ is the lifetime of protein without the quencher. The average value of 
fluorescence lifetime used was about 10" (Lakowicz & Weber, 1973). The 
molecular quenching rates constant were of the order of 10 L mol s . This 
was greater then the maximum limiting diffusion constant Kjif of the 
biomolecule (/Cdif =2.0x10 Lmol" s' ) (Gao et al., 2004), suggesting the static 
type quenching procedure was involved in complex formation. 
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Figure 3.6 Stem-Volmer plot for the binding of liistone H3 witli EPI (A) and 
iVITX (B). The plot represents the binding of the drugs at 298 (o), 302 (•), 306 
(T)and310(A)K. 
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Table 3.1: 
(A) Temperature effect on quenching constants of histone H3-EPI system 
T(K) 
298 
302 
306 
310 
/Csv xlO"^  
(Lmol"^ ) 
3.78 ±0.06 
3.63 ± 0.04 
3.48 ±0.12 
2.92 ±0.15 
Kq x lO" 
(LmolV) 
3.78 ± 0.06 
3.63 ±0.04 
3.48 ± 0.12 
2.92 ±0.15 
R' 
0.983 
0.995 
0.996 
0.996 
KxlO^ 
(mol" )^ 
0.11 ±0.22 
0.15 ± 0.06 
0.22 ±0.14 
0.26 ± 0.26 
n 
0.84 
0.89 
0.94 
0.95 
(B) Temperature effect on quenching constants of histone H3-MTX system 
T{K) 
298 
302 
306 
310 
Ks^J XlO"^ 
(Lmo|-^ ) 
5.93 ± 0.04 
4.22 ± 0.04 
2.47 ± 0.15 
1.60 ±0.12 
Kq x lO" 
(Lmor^ s"^ ) 
5.93 ± 0.04 
4.22 ± 0.04 
2.47 ±0.15 
1.60 ±0.12 
R' 
0.956 
0.920 
0.993 
0.995 
KxlQ-^ 
(mol') 
0.13 ± 0.22 
0.15 ±0.06 
0.17 ± 0.14 
0.20 ±0.26 
n 
0.85 
0.86 
0.88 
0.89 
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The procedure of quenching was further confirmed by studying the 
temperature dependence pattern of quenching parameters, which can 
differentiate between the dynamic and static quenching. The /fsv values 
decreased with an increase in temperature for static quenching and the 
reverse will be observed for dynamic quenching. 
The trend in the present study (Table 3.1) indicates that the probable 
quenching mechanism of histone H3 fluorescence by EPI and MTX is a static 
type. When ligand molecules bind independently to a set of equivalent sites 
on a macromolecule, the equilibrium between free and bound molecules is 
given by the equation (Gao et ai, 2004): 
log [(Fo -n / f ] = log /C + n log[Q] (5) 
where K and n are the binding constant and the number of binding sites, 
respectively. Thus, a plot of log (fo-F)/F versus log [QJ (Fig. 3.7, A & B) can be 
used to determine K as well as n. The values of K and n at 298, 302, 306 and 
310 K, were reported in table 3.1 (A & B) for EPI and MTX, respectively. The 
binding constant increased with increase in temperature, suggestive of the 
endothermic process. Meanwhile, from the data of n it may be inferred that 
there is one (si) site of binding for the drugs. 
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Figure 3.7 The plot of log [(Fo-F)/F\ versus log [Q] for EPI(A) and MTX(B) 
binding. Representative binding isotherms, for the temperature dependent 
binding constants and binding sites. The plot represents the binding of the 
drugs at 298 (o), 302 (•), 306 (T) and 310 (A)K. 
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3.3.5 Thermodynamic analysis 
Considering the dependence of binding constant on temperature, a 
thermodynamic process was considered to be responsible for this interaction. 
Therefore, the thermodynamic parameters dependent on temperatures were 
analyzed in order to further characterize the acting forces between the drugs 
and histone H3. The acting forces between a small molecule and 
macromolecule mainly include hydrogen bonds, van der Waals forces, 
electrostatic forces and hydrophobic interaction forces. The thermodynamic 
parameters, enthalpy change (AW), entropy change (AS') and free energy 
change (AC) are the main evidences to determine the binding mode. The 
thermodynamic parameters were evaluated from van't hoff plot (Fig. 3.8, A & 
B), using the following equations: 
ln/C= -AW°//?r + AS"//? (6) 
A(r = AH" - US' (7) 
where K and R are the binding constant and gas constant, respectively. The 
results obtained are shown in table 3.2, were suggestive that the process is 
entropically driven. The positive entropy change occurs because the water 
molecules that are arranged in an orderly fashion around the ligand and 
protein acquire a more random configuration as a result of hydrophobic 
interactions. The negative sign for A6° indicates the spontaneity of the 
binding of the drugs. 
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0.00315 0.00320 0.00325 0.00330 0.00335 0.00340 
1/T(K) 
(B) 7.7 
0.00310 0.00315 0.00320 0.00325 
1/T(K) 
0.00330 0.00335 0.00340 
Figure 3.8 Vant hoff plot for the binding of histone H3 with EPI (A) and iVITX 
(B), respectively. 
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Table 3.2: 
(A) Thermodynamic parameters for histone H3-EPI complex 
T(/0 AG'IWmol'^) AH*(Wmor^) Z\S° (JmolV) 
298 -12.0910.35 33.47 ±0.14 40.77 ±0.21 
302 -12.25 ±0.35 33.47 ±0.14 40.77 ±0.21 
306 -12.42 ±0.35 33.47 ±0.14 40.77 ±0.21 
310 -12.58 ±0.35 33.47 ±0.14 40.77 ±0.21 
(B) Thermodynamic parameters for histone H3-IVITX complex 
T(/0 A6*(/amor^) AH'(/amor^) AS*(Jmol'V) 
298 -08.10 ±0.51 16.30 ±0.18 27.25 ±0.33 
302 -08.21 ±0.51 16.30 ±0.18 27.25 ±0.33 
306 -08.32 ±0.51 16.30 ±0.18 27.25 ±0.33 
310 -08.43 ±0.51 16.30 ±0,18 27.25 ±0.33 
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with histone H3. Positive value of both AH' and AS° implies typical 
hydrobhobic interaction, while negative enthalpy and entropy changes arise 
from vander waals force and hydrogen bonding formation in low dielectic 
media (Ross & Subramanian, 1981). Moreover specific electrostatic 
interaction between ionic species in an aqueous solution is characterized by 
positive AS" and negative AH" value (Ying et al, 2007). For EPI and MTX 
complex with histone, the main source of AG" value is derived from a large 
contribution of AS" term as compared to the AH" factor, so the hydrophobic 
interactions dominate, but the electrostatic interaction can not be ignored in 
formation of the drug-protein complexes. The positive AH" values in the 
present study, signifies the endothermic reaction. The results are also in 
corroboration with our temperature dependence studies, depicting the 
stabilization of protein-drug complex with increase in temperature and 
highest at physiological temperature. Though the binding may decrease on 
increasing the temperature further but not realized in this study. 
3.3.6 Fluorescence resonance energy transfer (FRET) 
The spectral studies suggested that core histones form complex with these 
antitumour drugs. To further ascertain the proximity of the drugs with the 
core histone non-radiation energy transfer between the protein residue 
(donor) and the bound drugs (acceptor) could be determined using 
fluorescence resonance energy transfer (FRET). The distance between the 
donor and acceptor and extent of spectral overlaps determines the extent of 
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energy transfer. Generally, FRET occurs whenever the emission spectrum of a 
fluorophore (donor) overlaps with the absorption spectrum of another 
molecule (acceptor). The overlap of the UV absorption spectrum of EPI and 
MTX with the fluorescence emission spectra of core histones are shown in 
Figure 3.9 (A & B). The distance between the donor and acceptor can be 
calculated according to Forster's theory of dipole-dipole energy transfer 
(Forster & Sinanoglu, 1996). The efficiency of energy transfer, E is related to 
/?, the distance between the donor and the acceptor by 
E = l-F/Fo= ff*o / ff^o + r® (8) 
where F and FQ are the fluorescence intensities of core histones in the 
presence and absence of the drugs, r the distance between acceptor and 
donor and /?o is the critical distance when the transfer efficiency is 50%. 
/?% = 8.8xlO~"fc^/;"^<PJ (9) 
where k^ is the spatial orientation factor of the dipole, q the refractive index 
of the medium, 0 the fluorescence quantum yield of the donor and J is the 
overlap integral of the fluorescence emission spectrum of the donor and the 
absorption spectrum of the acceptor. J is approximated by the given 
equation: 
J-. Z f(A) c(A) X*AA (10) 
I F(\) AX 
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Figure 3.9 The overlap of the fluorescence spectrum of histone H3 (a) and the 
absorbance spectrum of the drug (b); [c{protein)/c(drug) = 1:1], for EPI (A) 
and MTX (B), respectively. 
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where f(X) is the fluorescence intensity of the fluorescent donor of 
wavelength, \ and e{\) is the molar absorption coefficient of the acceptor at 
wavelength, X. In the present case, the value of r^^  = 2/3, /? = 1.336 and 0 = 
0.118 were used (Lakowicz and Weber, 1973). From Eq. (8) to (10), we were 
able to calculate the molecular distance reported in table 3 and the efficiency 
of energy transfer was calculated to be f = 0.10 and E = 0.07 for EPI and MTX 
respectively. The distance between the compounds studied and the 
fluorophore residue was obtained and the r, distance between the acceptor 
and the donor was 1.86 and 2.07 nm for these compounds, respectively. The 
maximal critical distance for /?o is from 5 to 10 nm (Chen et ai, 1990) and the 
maximum distance between donor and acceptor for r is in the range 7-10 nm 
(Chen et ai, 1990). The values of /?o and r for EPI and MTX suggested that 
non-radiation transfer occurred between the drugs and the protein. A 
comparison of the J, RQ and r values of different ligands bound to protein is 
given in table 3.3. 
3.3.7 Effect of drugs on HAT activity 
Acetylation is one of the important post-transcriptional modifications of 
histones (Gray & The, 2001; Gregory et ai, 2001; Urnov et ai, 2002). After 
elucidation of EPI and MTX binding with histones core and H3; thereby 
implicating their interference with the vital process of acetylation by binding 
near the key lysines involved in the modification. Further to dissect other 
possible mode of interaction of these drugs with the process, we evaluated 
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Table 3.3: 
Comparative assessment of the EPI and MTX (ligand) distance to protein 
(histone H3) measured by Forster's nonradiative energy transfer with other 
ligands bound to Protein. 
Ligand 
Epirubicin (present study) 
Mitoxantrone (present study) 
Midazolam'^ 
Shikonin'' 
Bendroflumethiazide 
Quercetin^ 
Rutin^ 
Hyperin^ 
Baicalin^ 
Chlorogenic acid^ 
Feluric acid'' 
Genistein*^ 
Daidzein"^ 
Thiopental'' 
J 
(cm^ Lmol'^) 
1.86 X 10'^^ 
3.41 X 10"^^ 
1.09 X 10"^^ 
3.76 X lO"^ "* 
5.86 X 10"^^ 
1.35 X 1 0 ' " 
1.56 X 1 0 " 
1.57X l O " 
6.58 X lO'^"* 
1.32 X l O " 
3.76 X 10"" 
8.35 X 1 0 " 
9.28 X 1 0 " 
2.30X l O " 
(nm) 
1.44 
1.54 
1.69 
2.08 
1.55 
3.35 
3.43 
3.44 
2.97 
2.53 
1.95 
2.25 
2.29 
1.92 
r 
(nm) 
1.86 
2.07 
2.31 
2.12 
1.47 
3.78 
5.61 
5.05 
4.46 
3.57 
2.45 
3.68 
4.35 
2.32 
'(Bi et al., 2004); "(Kang et al, 2004); '(Mahesha et al., 2006); "(Khan et al.[\ & 
ii], 2008) 
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the effect of EPI and MTX on enzymatic activity of HATs. In order to determine 
whether drugs affect the enzyme activity, the total nuclear HAT was analyzed 
after treatment with different concentrations of EPI and MTX. The results 
indicated the dose dependent inhibition of the HAT activity. As compared to 
untreated cells the drugs significantly inhibit the HATs activity and lower the 
acetylation of the protein. Figure 3.10 (A & B), represents the drastic loss of 
HAT activity even at very low concentration of the drugs, which further 
reduced with the increasing concentration of the drugs. The inhibition was 
more prominent with the MTX as compared to the EPI. The positive control of 
0.1 mM TSA treated nuclear extract and the 15 min boiled nuclear extract was 
treated as negative control for more precise interpretation. Another set of 
experiment was employed to monitor the time incubation on drug inhibited 
HAT activity. Figure 3.11 (A & B), illustrated the time dependency on the drug 
induced repression of enzyme activity. Taken together these results imply 
that EPI and MTX inhibit HAT activity and repress acetylation. 
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Figure 3.10(A) Effect of epirubicin (EPI) on HAT enzyme activity. Samples were 
prepared with various concentrations of EPI. 50 \x.g nuclear extract was 
assayed for HAT enzyme activity as described in experiment overview (section 
3.2.10). Control represents the untreated sample. Samples boiled for 15 
minutes were used as a negative control and positive control as supplied. 
Cells were treated with the drug for as long as 0.5 h time course. Error bars 
represent the standard deviations for three independent experiments 
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Figure 3.10(B) Effect of mitoxantrone (MTX) on HAT enzyme activity. Samples 
were prepared with various concentrations of MTX. 50 |ag nuclear extract was 
assayed for HAT enzyme activity as described in experiment overview (section 
3.2.10). Control represents the untreated sample. Samples boiled for 15 
minutes were used as a negative control and positive control as supplied. 
Cells were treated with the drug for as long as 0.5 h time course. Error bars 
represent the standard deviations for three independent experiments 
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Figure 3.11(A) Time-effect of epirubicin (EPI) treatment on HAT enzyme 
activity. Fixed concentration of EPI (1.0 |iM) incubated for the indicated 
period of time was assayed to evaluate the time dependency on HAT activity 
inhibition. Error bars represent the standard deviations for three independent 
experiments 
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Figure 3.11(B) Time-effect of mitoxantrone (MTX) treatment on HAT enzyme 
activity. Fixed concentration of MTX (1.0 piM) incubated for tiie indicated 
period of time was assayed to evaluate the time dependency on HAT activity 
inhibition. Error bars represent the standard deviations for three independent 
experiments 
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3.3.8 Histone deacetyiase (HDAC) inhibition 
As from the above experiments it become clear that with the possibility 
to hinder acetylation by these drugs via binding near the vital lysine residues, 
they can further repress the process by inhibiting the HATs activity. But as the 
process of acetylation and deacetylation are opposing actions of HATs and 
HDACs (Gregory et ai, 2001; Urnov et ah, 2002). It may be possible that these 
drugs are causing induction of HDAC activity and the out come of suppressed 
HAT activity from the above experiment may be the resultant of this effect. To 
address the question we examine the effect of these drugs on the 
deacetylation activity of HDACs. Interestingly, the results indicated that EPI 
and MTX caused inhibition of HDAC. Figure 3.12, shows the dose dependent 
inhibition of HDAC activity by these drugs; though the inhibition observed was 
weak as compared to the positive control of TSA treated nuclear extract. 
Considering this result EPI and MTX are acting as an HDAC inhibitor. HDAC 
inhibition, although is antagonistic to the HAT inhibition (gene repression), 
but at the same time it induces the expression of repressed genes that 
produce growth arrest, terminal differentiation, and/or apoptosis in 
carcinoma cells (Johnstone ,2002; Marks et al., 2000). Due to which histone 
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Figure 3.12 Drug induced HDAC inhibition. Samples were treated with various 
concentrations of EPI (A) and MTX (B). Nuclear extract (50 ng) was assayed for 
HDAC enzyme activity as described in Experimental overview (section 3.2.11). 
Sample treated with 1 piM TSA was used as a positive control. 
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deacetylase inhibitors (HDIs) are emerging as a new class of anticancer agents 
for the treatment of solid tumors and hematological malignancies (RIchon & 
O'Brien, 2002; Marks et ai, 2001). 
3.3.9 Effect of drugs on histone acetylation in vivo 
Changes in the level of histones H3 acetylation at specific lysine residues 
in several malignancies (Liu et ai, 2008; Mahlknecht & Hoelzer, 2000), shows 
the importance of specific patterns of histone acetylation at N-terminal lysine 
residues for the final outcome of gene regulation. Since these drugs interact 
with the enzymatic machinery of histone acetylation besides its direct binding 
on the substrate protein. It becomes of immense interest to validate the 
interaction of these drugs with histone acetylation in in vivo conditions. 
By using anti-acetylated antibodies for histone H3 at K9 and K14 level of 
acetylation in drug treated cells and compared with the untreated 
counterparts. For this, cancerous HEK293 cells were treated with different 
concentration of EPI and MTX, which were further probed for acetylation of 
specific lysines. Differential pattern of acetylation was observed with different 
concentration of drugs. The acetylation reduced on the treatment of drugs in 
3 dose dependent manner (Fig. 3.13 & 3.14). As compared with the EPI, MTX 
lowed more prominent reduction. We analyzed the specific acetylation of 
and K14 to evaluate the drug induced effect on their acetylation. Similar 
results were observed for the both. Nuclear protein C23 and total histone H3 
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Figure 3.13 Representative, western blot analysis of histone H3 (Lysine 9/K9) 
acetylation. HEK293 cells were treated with different concentration of the 
drugs EPI (A) and MTX (B), to analyze the concentration dependent response 
of the drugs on H3 (K9) acetylation pattern. Figure is representative of three 
separate experiments. Samples with no antibody added were used as a 
negative control (control) and total H3 was used as the input control. 
91 
Chapter 3 
(A) 
DUMJ COIIC. ( f i ( j m l ) 
0.0 1.0 2.0 
13 
4.0 
AC-H3 |K14» 
Total *: 23 
(B) DnKjconc. ( ^< jm l ) 
0.0 1.0 2.0 4.0 
Coii t iol 
4^ MBS|i(H Ac H3 <K14> 
To t . l l €23 
C o n t i o l 
Figure 3.14 Representative, western blot analysis of histone H3 (Lysine 
14/K14) acetylation. 'HEK293 cells were treated with different concentration 
of the drugs EPI (A) and MTX (B), to analyze the concentration dependent 
response of the drugs on H3 (K14) acetylation pattern. Figure is 
representative of three separate experiments. Samples with no antibody 
added were used as a negative control (control) and nuclear protein C23 was 
used as the input control. 
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were taken as the loading controls and the gel developed without antibodies 
were referred as negative controls. 
Histone acetylation at the N-terminal lysines is associated with the 
transcriptional activation of specific genes (Wolfe et al., 1995). The role of the 
N-terminal tails in the histone on binding of anticancer drugs to the 
nucleosomal DNA has been discussed recently by Mir and Dasgupta (2004). 
They have shown that N-terminal tail domains block the access of external 
agents to the nucleosomal DNA. Acetylation of histone tails correlates with 
transcriptional activity in many genes, allowing DNA to unfold and providing 
access for transcription factors to bind on their targeted promoters. Hence, 
the reduced level of histone acetylation in the present case is suggestive 
repressed transcriptional activity on treatment with the tested drugs. 
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4.1 Introduction 
The ability of small molecules to interfere with transcription and DNA 
replication makes it a major target for drug interaction studies. Many natural or 
synthetic drugs serve as analogues in the research of protein-nucleic acid recognition 
and provide site-specific reagents for molecular biology. Therefore, the analysis of 
drug-DNA interaction is imperative for understanding the molecular mechanisms of 
the drug action and designing specific DNA-targeted drugs (Gilpin, 1997). Apart from 
interacting with proteins that bind to DNA or through DNA-RNA hybrids, small 
aromatic ligand molecules may bind to DNA double helical structures. Interactions 
may occur by (i) intercalating between stacked base pairs thereby distorting the DNA 
backbone conformation and interfering with DNA-protein interaction or (ii) as minor 
groove binders. 
The anthracyclines are one of the widely studied types of such drugs (Reszka 
et al., 1998) owing to their notably clinical efficacy against a wide range of 
malignancies (Plambeck et al., 1984). As a member of the anthracycline antibiotic, 
epirubicin (EPI) and mitoxantrone (MTX) were regarded as the most promising of 
anticancer drugs. They have major clinical value over other members of this group as 
EPI is among the few to reach the clinical development and approval status and MTX 
is an aglyconic anthracycline reported to be with less cardiotoxic effects compared 
with the naturally occurring anthracyclines, doxorubicin and daunorubicin 
(Kapuscinski et al., 1981). In multiple sdeorsis, MTX has also shown Its activity worth 
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of approval by the Food and Drug Administration (Gonsette, 2003). Although the 
reactivity's of these drugs with a range of cellular constituents are well known, but 
the specific cellular mechanisms involved and the ultimate cause of tumor cell death 
are still to be elucidated. The drug has a high affinity for DNA, thus providing the 
driving force for further nuclear uptake. It is well known that intercalation is the 
immediate form of interaction for naturally occurring anthracyclines and there is an 
extensive body of evidence to show that one of the first cellular responses is the 
impairment of topoisomerase 11 activity (Liu, 1989; Holm et ai, 1991). However, upon 
reductive activation, the drug can also bind covalently to DNA (Moore, 1977). The 
sequence specificity of a drug also governs its specific mode of action and its 
interference with specific regulatory mechanism. Recently some covalently binding 
agents have also been shown to disrupt the binding of transcription factors to their 
specific consensus sequences (Broggini & D'IncaIci, 1994). If these adducts prevent 
binding of transcription factors to DNA in tumor cells, then the sequence selectivity 
of the particular drug will determine which transcription factors are affected, and 
hence which genes are inhibited. The net effect of this process is that gene-specific 
inhibition may occur, depending on the sequence specificity of the particular drug 
adducts. In this study, we have evaluated the temperature dependence of binding of 
these drugs and thermodynamic parameters for this interaction. The effect of binding 
on conformation of the DNA was also assessed. The sequence specificity of these 
drugs and their interaction with the specific binding element was also analyzed. 
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4.2 Experimental overview 
4.2.1 l^aterials 
Highly polymerized type I calf-thymus DNA sodium salt (7% Na content) was 
purchased from Sigma Chemical Co. and was deproteinated by the addition of CHCI3 
and isoamyl alcohol in NaCI solution. Drugs were obtained as stated earlier. Other 
chemicals were of reagent grade and used without further purification. HEPES {4-{2-
hydroethyl)-l-piperazineethane sulfonic acid) buffer salt was from Sigma Chemical 
Corporation. 
4.2.2 Preparation of stocl( solutions 
Calf thymus DNA was dissolved to 0.5% w/w in 0.1 M HEPES buffer (pH 7.4) at 
298 K for 24 h with occasional stirring to ensure formation of homogeneous solution. 
The purity of the DNA solution was checked from the absorbance ratio AifjAiso-
Since the absorption ratio of the above purified DNA lies in the range 1.8 < A26oM28o> 
1.9, therefore no further purification was needed. The stock solution of the drugs 
with 5 mg/ml concentration was also prepared. 
4.2.3 Fluorescence spectroscopy 
Fluorescence measurements were made on a Shimadzu spectrofluorometer, 
model RF-5301PC (Shimadzu, Japan) equipped with a 150W Xenon lamp. The 
fluorescence quenching of drugs at increasing molar ratios of drugs to DNA was 
recorded in the wavelength range 500-600 for EPI and 640-740 nm for MTX after 
exciting the drug solution at 475 and 610 nm, respectively using 3nm/3nm as slit 
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widths. The drug concentration was fixed at 50 \xM unless mentioned and the DNA 
concentration was varied from 5 to 55 piM. To evaluate the effect of temperature at 
drug-DNA interaction, fluorescence was recorded at three different temperatures i.e. 
298, 306 and 310 K. The instrument was thermostatically controlled by a Neslab RTE-
110 circulating water bath. 
4.2.4 Stoichiometric analysis 
The stoichiometry of interaction of drug with DNA was determined by the 
method of continuous variations (Rahman et o/., 1993). The fluorescence change (A 
F=Ffluor - Ffluor+DNA) of a series of protein drug mixture was done, keeping the 
molarity of the mixture constant while varying the mole fraction of each. 
4.2.5 Absorption spectroscopy 
The UV measurements of calf thymus DNA were recorded on a Shimadzu 
double beam spectrophotometer model-UV1700 using a cuvette of 1 cm path length. 
Absorbance value of DNA in the absence and presence of complex were made in the 
range of 240-300 nm. DNA concentration was fixed at 0.1 mM, while the compound 
was added in increasing concentration. 
4.2.6 Fourier transform infrared spectroscopy (FTIR) 
Infrared spectra of nucleic acid solution were recorded on a Nicolet Magna 
750FT-IR spectrophotometer (DTGS detector, Ni-chrome source and KBr beam 
splitter) with resolution of 4 cm"^  and 60 scans. Spectra processing procedures: 
spectra of sample solution and buffer solution were collected at the same condition. 
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Then the absorbance of buffer solution was subtracted from the spectra of sample 
solution to get the FT-IR spectra of DNA. 
4.2.7 Molecular modeling study 
The crystal structure of B-DNA used for docking was extracted from the structure 
having Protein Data Bank (PDB ID: 453D). The 3D structure of IOC was generated in 
Sybyl 6. and its energy-minimized conformation was obtained with the help of the 
charm force field. Waters were removed from the DNA PDB file. Polar hydrogen 
atoms and Gasteiger charges were added to prepare the DNA molecule for docking. 
Rotatable bonds in the ligands were assigned with Auto Dock Tools in AutoDock. 
Ligand docking was carried out with the AutoDockv4.0, Lamarckian Genetic 
Algorithm (GA). DNA was enclosed in the grid defined by Auto Grid having 0.375 "A 
spacing. Other miscellaneous parameters were assigned the default values given by 
the AutoDock program. 
4.2.8 Circular dichroism (CD) 
Circular dichroism (CD) measurements of DNA in presence and absence of 
drug was made in the range of 220-320 nm region on a Jasco-J820 
spectropolarimeter coupled to a microcomputer using a quartz cell of 0.1 cm. All the 
spectra were recorded at 298K and the temperature was maintained constant by a 
thermostatically controlled Neslab RTE-110 circulating water bath. A stock solution of 
each of 150 \iM DNA was prepared in 0.1 M HEPES buffer. The molar ratio of DNA to 
drug concentration was 1: 0,1:2 and 1:4, for CD measurements. 
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4.2.9 Plasmid nicking assay 
Covalently closed circular plasmid pBR322 DNA (0.25 jig) in a final volume of 30 
Ml were treated with varying concentrations of the drugs and exposed to white light 
for 2 h. To this, 6ml of 5X tracking dye (40 mM EDTA, 0.05% bromophenol blue and 
50% (v/v) glycerol) was added and loaded onto 0.8% agarose gels. The gel was run at 
50 mA for 3 hrs and stained with ethidium bromide (0.5 ng/ml), for 30 min at 4 "C. 
4.2.10 Electrophoretic mobility shift assay (EMSA) 
The electrophoretic mobility shift assay was performed by using the double-
stranded synthetic oligonucleotides mimicking the octamer consensus motif 
ATGCAAAT. The synthetic oligonucleotides were end-labelled using [^ ^P] ATP and T4 
polynucleotide kinase (MBI Fermentas). Drug-DNA reactions were set up in a total 
volume of 25 nL containing HEPES buffer plus 5% glycerol, 5 mM dithiothreitol, 7.5 
mM MgCb, 0.1-6.0 [iM of the tested drug and 0.25 ng of ^^P-labelled 
oligonucleotides. Reactions were allowed to proceed for up to 9 h. When crude 
nuclear extracts isolated from human cell lines (HEK293) were used, the binding 
reaction was carried out in the presence of the nonspecific competitor poly (dl-dC): 
poly(dl-dC) (Dignam et al., 1983). After 20 min binding at room temperature, the 
samples were electrophoresed at constant voltage (200 V) under low ionic strength 
conditions (0.25 M Tris/acetate/EDTA buffer) on 6% polyacrylamide gels. Gels were 
dried and subjected to standard autoradiographic procedures and phosphoimager for 
more sensitive detection. 
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4.3 Results and Discussion 
4.3.1 Fluorescence measurements 
The interaction of the two anthracyclines with DNA was examined by 
monitoring the changes in the intrinsic fluorescence of EPI and MTX at varying 
concentrations of the drugs. The fluorescent emission spectra of the drugs as well as 
the effect of DNA concentrations on the fluorescence emission spectra were 
illustrated in figure 4.1. EPI and MTX exhibited an emission maximum at 560 nm and 
610 nm (Fig. 4.1 (A) & (B), curve a). The fluorescence emission was gradually 
decreased with increasing amount of DNA, showing that the drug fluorescence was 
efficiently quenched upon binding to DNA. Since the highest change in the drug 
fluorescence spectra on addition of DNA occurred at the wavelengths at 560 for EPI 
and 610 for MTX, the fluorescence measurements at these wavelengths yielded 
accurate determination of bound fraction. When the concentration of DNA was up to 
25 X 10'^  M, the fluorescence intensity of MTX was almost completely quenched and 
a slight shift in its peak maxima was observed, which was not with the case in EPI, 
indicating the binding reached saturation earlier in MTX than in EPI. The red shift on 
MTX titration indicate that on binding to the DNA the ring substituents on the 
fluorophore could slide into the base pairs, illustrating that they were in an 
environment in which it was unable to H bond with the solvent water molecules. The 
red shift observed at lower concentration of DNA in case of MTX as compared with 
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Figure 4.1(A) Representative emission spectra of epirubicin (EPI) in the absence and 
presence of increasing amount of DNA at 298 K. The spectra illustrate the progressive 
quenching of EPI fluorescence on titration of the DNA. Curve a, depicts the emission 
of the drug (50 \M), curve b-l corresponds to DNA concentration 5,10,15, 20 25, 30 
35, 40, 45, 50 & 55 ^M. Curve x, represents the emission of DNA alone at the 
scanned wavelength. 
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Figure 4.1(B) Representative emission spectra of mitoxantrone (MTX) in the absence 
and presence of increasing amount of DNA at 298 K. The spectra illustrate the 
progressive quenching of MTX fluorescence on titration of the DNA. Curve a, depicts 
the emission of the drug (50 piM), curve b-l corresponds to DNA concentration 5,10, 
15, 20 25, 30 35, 40, 45, 50 & 55 |iM. Curve x, represents the emission of DNA alone 
at the scanned wavelength. 
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EPI, also indicated the higher affinity between DNA-MTX complex than with DNA-EPI 
complex. The Stern-Volmer quenching plot from the fluorescence titration data was 
shown in figure 4.2. The fluorescence quenching constant (/fsv) was evaluated using 
the Stern-Volmer equation (Firdaus et ai, 2008): 
f o / f = l + 'fsvIDNA] (1) 
where FQ and F are the fluorescence intensities in the absence and presence of DNA, 
respectively, K%M is the Stern-Volmer quenching constant, which is a measure of the 
efficiency of quenching by DNA. The titration data were used to construct a plot of 
FQ/F versus [DNA]. K^M obtained from the slope of the linear line was 0.49 x 10^ and 
0.45 x 10^ Lmol"^ for EPI and MTX respectively. The Stern-Volmer plot is linear, 
indicating that only one type of quenching process occurs, either static or dynamic 
quenching (Lakowicz, 2006). The procedure of quenching was further confirmed from 
the values of bimolecular quenching rate constants, Kq, which are evaluated using 
the equation: 
Kq = Ksw/To (2) 
where TQ is the lifetime of protein without the quencher. Since fluorescence lifetimes 
are typically near 10"^ s, the bimolecular quenching constant (Kq) was calculated 
from the above equation and was found to be of the order of l O " m o r V \ By 
considering the equivalency of the bimolecular quenching constants, it can be seen 
that the latter is greater then the largest possible value (Ixio^^mol"^ s"^ ) 
103 
Cfiapter 4 
Figure 4.2 Stern-Volmer plot for the binding of DNA with EPI (A) and IVITX (B). The 
plots represents the binding of the drugs at 298 (•), 306 (o) and 310 {T)K. 
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(Lakowicz, 2006) in aqueous medium. Thus the fluorescence quenching is not 
initiated by a dynamic process but is rather due to a static process with ground state 
complex formation. The quenching procedure was further assured by temperature 
dependence of quenching. Studying the temperature dependence pattern of 
quenching parameters can differentiate between the dynamic and static quenching. 
The /fsv values decrease with an increase in temperature for static quenching and the 
reverse will be observed for dynamic quenching. The trend in the present study 
(Table 4.1) indicates that the probable quenching mechanism of EPI and IVITX 
fluorescence by DNA is a static type. Our results also corroborate with the number of 
research of its anthraquinone analog (Zhong et al., 2001). 
4.3.2 Equilibrium binding titration 
When ligand molecules bind independently to a set of equivalent sites on a 
macromolecule, the equilibrium between free and bound molecules is given by the 
equation (Firdaus etal., 2008): 
log m -F)/n = log /C + n log[Q] (3) 
where /f and n are the binding constant and the number of binding sites, respectively. 
Thus, a plot of log {FQ -f)/F versus log [QJ (Fig. 4.3, A & B) can be used to determine K 
as well as n. The values of K and n at 298, 306 and 310 K (Table 4.1), suggests the 
destabilization of EPI-DNA and MTX-DNA complex with the increase in temperature. 
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Figure 4,3 Binding isotherm of log [(Fo-F)/F] versus log [Q]. The plots represent the 
temperature dependent binding of EPI (A) and MTX (B) with DNA. 
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Table 4.1 
(A): Effect of temperature on the binding of EPI witli DNA. 
T{K) KsvxlO^ KqxlO^^ K n r^ 
(Lmol'^ ) (LmolS'^) (x 10^ Lmoi"^ ) 
298 06.98 ±0.12 06.98 ±0.12 06.60 ±0.16 1.17 0.9968 
306 05.48 ±0.08 05.48 ±0.08 04.36 ±0.04 1.17 0.9921 
310 04.91 ±0.09 04.91 ±0.09 02.51 ±0.06 1.28 0.9864 
(B): Effect of temperature on the binding of MTX with DNA. 
T(K) /fsyxlO"* / fqx io " K n r^ 
(Lmor^) (Lmol'^ s"^ ) (x 10^ LmoP )^ 
298 11.68 ±0.07 11.68 ±0.07 12.02 ±0.08 1.33 0.9864 
306 06.53 ±0.18 06.53 ±0.18 07.58 ±0.21 1.24 0.9921 
310 04.56 ±0.06 04.56 ±0.06 05.01 ±0.12 1.22 0.9968 
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4.3.3. Stoichiometric analysis 
Determination of stoichiometry of the DNA-drug complexes was done using 
Job's plot or mole-ratio method. In this method, DNA and drugs solutions with 
equimolar concentrations were mixed in different amounts such that the total 
number of moles of reactants in each mixture was kept constant. The molar ratio of 
reactants was varied across the set of mixtures. Fluorescence of each solution was 
then measured at the respective emission maxima of the drugs, which was plotted 
against mole fraction of one of the reactants (drug in this case). The breakpoint in the 
plot corresponds to the mole fraction of the drug in the DNA-drug complex and 
thereby gave the binding stoichiometry. The analysis and interpretation are simpler 
if, as in the present case, the DNA molecule has no flourophore in the range of 
wavelength scanned here. The relative fluorescence observed is directly proportional 
to the drug concentration as present in the complex. As evident from the Job's plot 
(Fig. 4.4, A & B), a clear breakeven point implies that the stoichiometric ratio of 
EPI:DNA and MTX:DNA at 298 K and pH 7.4 is 2:1 and 1:1 respectively. 
4.3.4 Determination of thermodynamic parameters 
The thermodynamic parameters, LH and AS were evaluated from the following 
equation: 
log ^ = - Ltr/ 230SRT + AS7 2.303/? (4) 
108 
Cfia-pter 4 
Mole fraction of DNA 
Mole fraction of DNA 
Figure 4.4 Job's plot based on the method of continuous variation. Depicting the 
stoichiometry of the DNA with EPI (A) and MTX (B) at 298 K. 
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Figure 4.5 Representative Van't Hoff plot for the interaction of EPI (A) and MTX (B) 
with DNA in 10 mM HEPES buffer, pH 7.4. 
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where R and Tare the universal gas constant and absolute temperature, respectively. 
The K values were determined at three different temperatures and a van't Hoff plot 
of In/C vs 1/T gave a straight line (Fig. 4.5, A & B). The AH and AS values were obtained 
from the slope (-AW//?) and intercept (AS//?) of the van't Hoff plot. Knowing these two 
values, AG was calculated from the following standard equation (Castellan, 1989): 
A(r = AH"-r4S' (5) 
For both the drugs AG values were calculated at all three temperatures. It should be 
mentioned that we do not have an access to an isothermal titration calorimeter (ITC), 
which prevented us from determining thermodynamic parameters that are model 
independent. 
Table 4.2 shows the thermodynamic parameters of these EPI and MTX 
complexes with DNA. In both the cases, negative AG values were obtained which 
show that the binding was favoured. However, for the association, the binding 
enthalpy was +10.59 kcal/mol for EPI-DNA and +11.62 kcal/mol for MTX-DNA 
complex. Wherein, AS for EPI-DNA and MTX-DNA was evaluated to be +60.98 
kcal/mol and +63.10 kcal/mol, respectively. This clearly shows that the binding 
reaction is entropically driven in both the cases. For entropically driven drug-DNA 
interactions, the solvent molecules and the counter ions are expelled from the bound 
surface of both the interacting partners when they bind to each other, leading to 
entropic gain. 
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Table 4.2 
(A): Thermodynamic parameters for the binding of EPI with DNA. 
T(K) K AG' AAT AS" 
(xloHmor^) (kcalmol"^) (l<cal mol"^) (l<cal mol'^ K'^ ) 
298 06.6010.16 -18.16 ±0.27 10.5910.28 60.9810.82 
306 04.3610.04 -18.6410.24 10.5910.28 60.9810.82 
310 02.5110.06 -18.8910.28 10.5910.28 60.9810.82 
(B): Thermodynamic parameters for the binding of IVITX with DNA. 
T(K) K t^G" AH" AS" 
(xloHmo)"^) (l<calmol'^) (l<cal mol" )^ (l<cal mol"^ K"^ ) 
298 12.0210.08 -18.7910.17 11.6210.18 63.1010.72 
306 07.5810.21 -19.2910.18 11.6210.18 63.1010.72 
310 05.0110.12 -19.5410.16 11.6210.18 63.1010.72 
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This effect is counter balanced by the enthalpically unfavorable effects due to 
breakage of hydrogen bonds and non-covalent interactions of the solvent molecules 
and counterions with the uncomplexed partners. This is reflected in the positive 
value of enthalpy. On the other hand, the positive change arises from energetically 
unfavorable distortion of the DNA backbone at the binding site. It undergoes B to A 
type transition characterized by the widening of the minor groove to accommodate 
the bulky dimer complex (Aich et al.,1992; Aich and Dasgupta, 1995; Majee et 
al.,1997). In such entropically driven drug-DNA binding reaction, hydrophobic 
interactions are known to play a major role (Chaires, 1998; Haq, 2002). AS value for 
MTX interacting with DNA was found to be larger than EPI complex. It should be 
mentioned that the enthalpic contribution is more disfavoured in case of MTX 
complex which is expected if the MTX gets deeper into the hydrophobic DNA-
interior. 
4.3.5. Binding mode 
4.3.5.1. UV-Vis measurements 
UV-Vis absorption studies were performed to further ascertain the interaction 
of DNA with EPI and MTX. Figure 4.6 (A & B), showed the difference UV/Vis 
absorption spectra of DNA in the absence and presence of different concentrations 
of the drugs. The maximum absorbance of DNA was located around at 260 nm. It is 
well established that the absorption peak of the double helical DNA occurs at this 
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Figure 4.6 Differential UV/Vis absorption spectra of DNA (50 nM) in the absence and 
presence of EPI (A) and MTX (B) concentration: (a) 0; (b) 20; (c) 40 and (d) 80 ^ M. 
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wavelength. The UV absorbance showed a decrease in absorption bands with the 
increase in drugs concentration (Fig. 4.6, A & B). The decrease in the difference 
spectra of the DNA and the DNA-drug complexes is indicative of the complex 
formation between DNA and the drugs. The increase of the EPI and MTX in the DNA 
at the 260 nm exhibited hypochromism of 49% and 59 % and bathchromism of 10 
and 3 nm, respectively. This hypochromic effect is thought to be due to the 
interaction between the electronic states of the intercalating chromophore and 
those of the DNA bases (Fukuda et al., 1990). It is expected that the strength of this 
electronic interaction would decrease as the cube of the distance of separation 
between the chromophore and the DNA bases (Cantor et a\., 1980). So, obviously the 
large hypochromism observed in our experiments suggested the close proximity of 
the drug chromophore to the DNA bases. In addition, with the high concentration of 
DNA, the red shift in both of two maximum absorption peaks was observed by 20 
nm. After interaction with the base pairs of DNA, the n-n* orbital of the bound 
ligand can couple with the n orbital of the base pairs, due to the decrease n-n* 
transition energy, which results in bathochromic shift (He et al., 1998). This 
phenomenon indicated that upon binding to DNA the ring substituents on the 
chromophore could slide into the base pairs; as a result they would be in an 
environment in which it was unable to form Hydrogen bonds with the solvent water 
molecules. These changes are suggestive of the intercalative mode of binding. 
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4.3.5.2. Competitive binding of tlie drugs and EtBr with DNA 
In another set of experiment, we further authenticate the intercalation of these 
drugs, we plan a competitive displacement experiment. The ethidium bromide (EtBr) 
a typical intercalator was used to compete with EPI and MTX. EtBr is an intercalator 
that approaches the DNA backbone via the minor groove (Waring, 1981). Figure 4.7 
(A & B), shows three fluorescence spectra. The first spectrum is that 50 nM DNA with 
saturating EtBr. The second spectrum is that of 50 \iM DNA to which 25nM drug was 
added. After incubation for one hour, the same concentration of EtBr was added as 
in the case of the first spectrum. The third spectrum is that of 50 piM DNA to which 
identical concentration of EtBr is adided as the second spectrum followed by addition 
of 25 pM. As is evident, there is significant change in the fluorescence spectra when 
the drug (EPI or MTX) was added to DNA either before or after addition of the EtBr 
(Fig. 4.7, A & B). This shows that EtBr can be removed by the drugs to a larger extent 
which indicates that drugs strongly compete with EtBr to DNA backbone. Consistent 
with the large reduction in case of MTX than EPI, illustrates better competition of 
MTX among the two. Putting together the results obtained from UV absorption study 
and that of fluorescence studies, one can predict a possible intercalative mode of 
binding of EPI and MTX with the DNA. 
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Figure 4.7 Fluorescence spectra of 50 \iM DNA with saturating EtBr (curve a); 50 nM 
DNA with 25 ^M of EPt(A) and IVITX(B) incubated for one hour followed by addition of 
saturating EtBr (curve b); 50 nM DNA with saturating EtBr incubated for one hour 
followed by addition of 25 \iM EPI(A) and MTX(B) (curve c). 
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4.3.6. Sequence specificity of drug-DNA binding 
4.3.6.1. Fourier transform infrared (FTIR) measurements 
The spectral changes (intensity and shifting) of several prominent DNA signals 
in-plane vibrations at 1717 cm'^ (G, T), 1663 cm"^ (T, G, A and C), 1609 cm'^ (A, C), 
1492 cm"^  (C, G) and 1222 cm'^ (PO2 asymmetric stretch) (Alex & Dupuis, 1989; 
Neault & Tajmir Riahi, 1998; Nafisi et al., 2005) were monitored at different drug 
concentrations and the results are shown in Fig. 4.8 (A & B). The results further 
evident intercalation mode of binding with the minor intensity increase of DNA in-
plane vibrations at 1717 (G), 1663 (T), 1609 (A), and 1222 cm'^ (PO2 asymmetric 
stretch) upon EPI and MTX interaction (Fig.4.8, A & B). The major shifting of the band 
at 1717 (G) to 1698 and 1726 cm"^ in EPI and MTX, respectively is indicative of drug 
intercalation mainly into the G-C base pairs (Fig. 4.8, A & B). However, the thymine 
band at 1663 cm"^ exhibited no shifting upon drug complexation. The adenine band 
at 1609 cm'^ show increase in absorbance with almost no shift in the peak due to 
which it was difficult to draw a certain conclusion on the nature of drug interaction 
with A-T bases (Fig,4.8, A & B). At high drug (EPI and MTX) concentrations, a major 
increase in intensity of guanine band at 1717 cm'^ was observed accompanied with 
the shifting of this vibration, which is indicative of some degree of EPI and MTX 
external binding to guanine bases (Fig. 4.8, A & B). This illustrates the higher affinity 
of these drugs with G-C bases. Furthermore, the shifting of the PO2 asymmetric band 
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Figure 4.8 FTIR difference spectra of DNA in the absence and presence of increasing 
concentration of EPI (A) and MTX (B). Curve a-d corresponds DNA (3.0 mM) + drug (a) 
0 nM; (b) 3 nM; (c) 30 uM and (d) 300 ^ M . 
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at 1222-1224 cm"^  with increase in intensity of this vibration is due to the interaction 
of these drugs with the backbone PO2 groups. The higher increase in case of MTX 
than EPI suggests the stronger interaction of DNA backbone with the MTX (Fig. 4.8, A 
&B). 
4.3.6.2 Molecular modeling of EPI and MTX with DNA 
Docking studies provide some insight into the interactions between the 
macromolecule and ligand, which can corroborate the experimental results. Though 
the crystal structure of the complex can represent specific details of the interactions, 
general observations may be obtained from docking studies. The docked structure as 
shown in Fig. 4.9A & B, suggests that EPI and MTX could bind the DNA by interacting 
the bases and the phosphate backbone. The binding site of the drugs is 3 base pairs 
long. Figure 4.9 illustrates the interaction of the aromatic ring and the side chains of 
the drug moiety with the base pairs and the phosphate back bone of the DNA, which 
helps in better 'anchoring' and stabilization of the drug-DNA adduct. The analysis of 
the docking results further revealed the binding of the drugs at the G-C rich region. 
This corroborates with our previous results of higher G-C affinity of the drugs. 
4.3.7 Structural perturbation 
4.3.7.1 Circular dichroism (CD) measurements 
CD spectrum is a sensitive reporter of any alteration in the DNA-backbone. We 
have therefore used CD spectroscopy to identify the backbone distortions in the DNA 
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Figure 4.9 Molecular modeling of DNA binding with EPI (A) and iVlTX (B). 
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obtained upon binding of the drugs. Figure 4.10 (A, curve a), sliows the CD spectrum 
of 35 nM DNA with two different concentration of EPI. As the concentration of the 
drug was increased, there was a very distinct change in the CD-spectrum of the B-
form DNA. Similar changes were also obtained with increasing concentration of MTX 
added to a constant concentration of 35 ^M DNA [Fig. 4.10, B (curve a)]. It should be 
mentioned that the maximum changes were obtained in both cases at intermediate 
DNA or drug concentration (shown in this study). This is because at this drug 
concentration the maximum population is that of the bound DNA or vice versa, which 
is not the case with either high DNA or drug concentration. On increasing the 
concentration of DNA or the drugs the CD-contribution coming from free or unbound 
components masks the changes obtained in the CD spectra on DNA-drug complex. 
Hence, the CD data presented, exhibits substantial change in the ellipticity values, 
which clearly suggested the structural alterations in the DNA. Thus, in addition to 
surface binding of these drugs on DNA, the intercalation of EPI and MTX may induce 
substantial conformational changes in the DNA structure. 
4.3.7.2. Plasmid nicking assay 
Figure 4.11 (A & B), shows the agarose gel electrophoretic pattern of EPI and 
MTX treated plasmid (pBR322) DNA, respectively. Treatment of supercoiled DNA with 
the drugs resulted in complete transformation to relaxed open form. A noticeable 
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Figure 4.10 CD spectrum of DNA {30^M) in 10 mM HEPES buffer at pH 7.4 in tlie 
absence and presence of EPI (A) and MTX (B). The spectra represents (a) DNA alone 
(b) DNA+drug 7.5 [iW\ and (c) DNA+drug 15 \iM. 
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Figure 4.11(A) Agarose gel electrophorogram of plasmid pBR322 DNA treated with 
increasing of epirubicin (EPI). Control represents the untreated DNA (positive 
control), EcoR I digest represents the negative control, remaining three lanes shows 
the effect of drug treatment of conformationai transition of DNA. 
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Figure 4.11(B) Agarose gel electrophorogram of plasmid pBR322 DNA treated with 
increasing of mitoxantrone (MTX). Control represents the untreated DNA (positive 
control), EcoR I digest represents the negative control, remaining three lanes shows 
the effect of drug treatment of conformational transition of DNA 
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reduction in the intensity of the band corresponding to covalently closed circular 
(CCC) form of plasmid DNA occurred with a concomitant increase in the amount of 
nicked species. Similar results were obtained with both the drugs, though the degree 
of relaxation differs among them, which mainly relies on the extent of interaction of 
the EPI and MTX with the DNA. Higher the interaction affinity, higher will be the 
degree of relaxation as found in case of MTX compared to EPI at same concentration. 
These transformations of covalently closed circular structure into nicked or relaxed 
species with increasing drug concentration clearly suggest strand scission of DNA, 
resulting in structural perturbation of the nucleic acid. 
The above two experiments suggest structural and conformational 
perturbation of the DNA on interaction of EPI and MTX. These changes in the DNA 
structure can be translated as a hindrance in specific structure-activity relationship, 
which is prerequisite for many vital processes. 
4.3.8. Effect of drugs on transcription complex formation 
The ability of these drugs to inhibit transcription factor (TF)-DNA complex 
formation was analyzed by using EMSA assay. The octamer motif is important for 
promoter activation mediated through generally expressed Oct-1 protein, such as the 
histone H2B and snRNA genes (reviewed by Herr, 1992). The octamer element is also 
a target-binding site for octamer factors (Sturm et al., 1991) encoded by the Brn-2 
POD domain gene (Schreiber et al., 1993; Thomson et al., 1995). Hence, we chose 
octamer consensus motif for EMSA. Initial studies were performed to establish at 
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levels would EPI and MTX binding would prevent octamer protein binding to their 
consensus motif. The crystal structure of Oct-1 bound to ATGCAAT revealed that 
major contacts of the specific domain of Oct-ldirectly to the GC within the sequence 
(Klemm et al., 1994). Due to the predicted specificity of the drugs from above 
experiment and supported by the tetracyclic structure of these drugs suggests that 
binding of these drugs at GC site would pose a direct blockage to TF-DNA interaction. 
Figure 4.12(A), shows that there is an EPI concentration-dependent inhibition of 
octamer binding with the consensus motif. To avoid the non-specific art effect 
binding reaction was carried out in the presence of the nonspecific competitor poly 
(dl-dC):poly (dl-dC). Similar results were found in case of MTX [Fig. 4.12(B)]. Overall, 
the inhibition of binding of octamer proteins correlates well with the known 
characteristics of formation of anthracycline induced adducts. Although these trends 
are quite clear and highly reproducible, there was some variation in the absolute 
level of formation of octamer protein-DNA complexes and that could be explained 
due to the varying concentration of transcription factors present in individual nuclear 
extracts (Thomson etai, 1993). 
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Figure 4.12(A) Gel retardation assay of inliibition of binding by octanner proteins with 
increasing concentration of epirubicin (EPI). The octamer binding probe (H2B gene) 
was exposed to 0.1-5.0 |iM of EPI for an incubation period of 12 h. Control samples 
were incubated In the absence of drug in the reaction buffer. The reacted probe was 
exposed to nuclear extract from HEK293 cells. Electrophoretically retarded bands 
denote protein-DNA complexes due to Oct proteins present in the nuclear extract. 
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Figure 4.12(B) Gel retardation assay of inhibition of binding by octamer proteins with 
increasing concentration of mitoxantrone (MTX). The octamer binding probe (H2B 
gene) was exposed to +0.1-5.0 [xM of MTX for an incubation period of 12 h. Control 
samples were incubated in the absence of drug in the reaction buffer. The reacted 
probe was exposed to nuclear extract from HEK293 cells. Electrophoreticaily retarded 
bands denote protein-DNA complexes due to Oct proteins present in the nuclear 
extract. 
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5.1 Introduction 
The chemotherapeutic approach for the treatment of cancer is still unsuccessful. 
This is mainly due to the lack of discovery of new effective anticancer drugs, the 
severe side effects associated with conventional chemotherapy and the possible 
instaurance of the multidrug resistance, often induced by cytotoxic agent 
administration, innovative ideas and new strategies are therefore needed in order to 
overcome these obstacles and to obtain the selective destruction of neoplastic cells. 
To this aim, an optimal insight into the mechanisms of action at subcellular and 
molecular level of the antitumoural agents and the identification of their cellular 
targets, constitute indispensable stages. Antineoplastic drugs generally have a 
narrow therapeutic index and are delivered at doses close to toxicity. Endogenous 
factors affecting drug response involve genetic predisposition, disease states and 
other factors that influence absorption, distribution, activation and detoxification of 
the drug. In particular, the pharmacological activity of any genotoxic anticancer drug 
is strictly dependent on tumour-specific physiological/biochemical conditions, such 
as a functional respiratory chain (Albin et al., 1993; Meister, 1995) and the 
presence/absence of drug metabolizing enzymes (Hercbergs et al., 1992; Tew, 1994; 
O'Dwyer et al, 1995). Epirubicin (EPI) and Mitoxantrone (MTX), analogues of the 
anthracycline antibiotics, belongs to the anthracenediones, a class of synthetic 
chemotherapeutic agents. The mode of action of these drugs has not yet been clearly 
established. Among others, these drugs exhibits a range of intracellular effects, the 
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most dominant of which appears to be the induction of DNA damage and apoptosis. 
Programmed cell death or apoptosis is an essential homeostatic mechanism in 
multicellular organisms allowing the elimination of no longer needed or seriously 
damaged cells by an orderly process of cellular disintegration. Depending on the 
organism, apoptosis involves a typical set of morphological events including 
chromatin condensation (Clifford ef al., 1993; Haupt et al., 1996), DNA and nuclear 
fragmentation, cell shrinkage, plasma membrane blebbing, increased numbers of 
cytosol vacuoles and formation of apoptotic bodies followed by phagocytes digestion 
(Darzynkiewicz et al., 1992; Ellis et al., 1991). It has been demonstrated that 
molecular pathways leading to the apoptotic phenotype are also present in yeast, 
and developed before the evolutionary separation of fungi and metazoan organisms 
(Ameisen, 1996; Xu & Reed, 1998). In the present study, we used yeast 
Saccharomyces cerevisiae as an experimental model, can be easily handled to 
evaluate different biological effects (inhibition of cellular growth, cytotoxicity and 
genotoxicity) induced by the drugs considered. The usefulness of eukaryotic 
organisms such as yeast in drug genotoxicity screening has been demonstrated 
earlier (Poll ef al., 1999; Rossi, 1997; Bozzola & Russel, 1999). In this study, we have 
tried to clarify basic cellular mechanism mediating the biological action of anticancer 
treatments and understanding the possible inflection of drug action by a holistic 
interaction of many cellular systems. 
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5.2 Experimental overview 
5.2.1 Materials 
2,3,5-triphenyl-tetrazolium chloride, Propidium Iodide and giuteraldehyde 
were purchased from Sigma. Ail solutions were prepared freshly in sterile Milli-Q 
water or phosphate buffered saline (PBS, pH 7.4). Biochemicals: yeast extract, bacto 
peptone and dextrose were obtained from Himedia, India. All other solvents and 
reagents used were of analytical grade. 
5.2.2 Yeast strain and culture medium 
The experiments were carried out with the haploid yeast Saccharomyces 
cerevisiae strain from Clontech laboratories (AH 109) mating type a. Cells were grown 
in yeast extract, peptone and dextrose (YPD) broth on orbital shaker at BO'C. Cells 
were picked from the culture during exponential growth phase at OD between 2 and 
4 at 700 nm, and cultures were diluted with fresh medium in order to obtain a 
density of 10^ cells /ml (OD7oo= 0.5) 
5.2.3 Growth inhibition 
Inhibition effect of the drugs on the growth of the yeast cells was determined. 
The cells were inoculated at lO'' ceils/ml and, after 2 h incubation, cell division 
inhibition was evaluated as a percentage with respect to dose 0 for each) at each 
drug concentration. 
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5.2.4 Survival assay 
In another set of experiment, yeast cells were incubated overnight in YPD 
media, inoculated to a fresh YPD media at OD700 of 0.1, incubated at SO'C for 8 h, 
treated with various concentration of drug, diluted in sterile deionized water at 10^ 
spread onto YPD plates, and colony forming unit (cfu) was determined. Cfu's of the 
drugs-treated cells were compared with those of untreated cells and expressed as 
percent survival frequency (cfu %). The survival ratios were expressed as mean values 
with standard error of mean ± SD of at lease three independent experiments. 
5.2.5 Fluorescence labeling with propldium iodide 
To explore the desired aspects with the respective instruments the untreated 
control and the tested samples were immediately incubated with propidium iodide 
(PI), an impermeable nucleotide-binding probe. A 5-ml aliquot of 20 mM PI solution 
in PBS was mixed with a 3-ml of the samples. Samples were thoroughly mixed by 
pipetting up and down several times, and incubated in the dark at 25 "C for 15 min. 
5.2.6 Confocal laser scanning microscopy (CLSM) 
Confocal microscopy images were acquired to asses the effect of drug on 
normal cell growth. Leica TCS SP2 confocal system attached to a research Leica DM 
RXA2 microscope (Heidelberg, Germany) fitted with a water immersion dipping 
objective lens (60X) and a Kr-Ar Laser. The specimens were stained for 1 h with PI 
(0.2 mg/ml) in a buffer containing 0.1% sodium citrate, 0.1 mg/ml RNase and 0.3% 
Brij-58. The excitation wavelength was 594 nm. A scan speed of 400 lines s'^  was used 
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to ensure minimum dislocation due to the movement of the cells. Images of the 
colour were adapted to the 8-bit range of system. An HCX PL APO CS 63.0 x 1.32 Oil 
UV objective was used with an additional zoom of 4 x, resulting in a 512 x 512 image 
with a pixel size of 0.12 |im. The pinhole size was set at lAIRY Disc. Series through the 
whole thickness of the biofilm were made with a stepsize of 0.04 \im. The Kr-Ar lasers 
were used at 30% and 45% power, respectively, to minimize photobleaching. Each 
sample was scanned at 5 randomly selected positions away from the disk edge. Each 
stack of an experiment was examined and the threshold value that best fit all image 
stacks of a trial was chosen. The images of control and test samples were averaged 
and compared. 
5.2.7 Fluorescence spectroscopy 
A spectrofluorimeter (shimadzu, Japan), equipped with a 490-nm excitation, 
filter was scanned 520-605 nm wavelength. The degree of membrane damage was 
assessed by PI binding to cellular DNA in terms of fluorescence intensity units. 
Isopropanol-treated cells gave the highest fluorescence intensity reading; thus, 
fluorescence of all treatments was reported as a relative fluorescence of this control. 
5.2.8 Flow cytometry 
Flow cytometric analyses were done by Coulter Epics Elite flow cytometer 
(Beckman Coulter France S.A., Paris, France) with 488 nm excitation by an argon-ion 
laser at 15 mW. Discriminators were set on forward (FSC) and side (SSC) scatter 
signals to reduce electronic and small-particle noise. The optical filters were set so 
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that PI fluorescence was measured at 610 nm and BOX fluorescence at 525 nm. In all 
cases, there was some spectral overlap between the emitted fluorescence of the 
stain mixtures. Therefore, the compensation of the system was set to eliminate 
interference. Positively and negatively stained controls for each osmotic pressure 
were used to achieve compensation and exclude the contribution of signals from the 
yeasts. Flow-rate was 300 cells sec'\ Each measurement acquired counted for the 
analysis of 10^ treated cells. Typically, signals from 10,000 cells were acquired and 
analyzed for each sample using the Window Multiple Document Interface for Flow 
Cytometry (Win MDI) 2.8 software. The flow cytometry results presented in this 
study are representative of at least three independent experiments. 
5.2.9 Yeast two hybrid system 
(a) Colony lift p-galactosidase assay 
Doubly transformed yeast colonies were grown in absence and presence of 
increasing concentrations of the drugs. Then, colony lift or filter |3-gal assay was 
performed by picking cells onto filter paper. Yeast cells were permeabilized by 
freezing yeast-impregnated filters in liquid nitrogen and thawing at room 
temperature. The filter was placed over a second filter that was presoaked in 0.1 M 
phosphate buffer saline (pH 7.4) containing 300 mg/ml 0-nitrophenyl-D-galactoside 
(X-gal) and 0.27% 6-mercaptoethanol. Filters were left for 8 hrs at 30 °C to develop a 
blue color. The colour of the sample without drug treatment was considered as 
normal expression of the P-Galactosidase (control). P-Galactosidase expression levels 
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were determined using 0-nitrophenyl-D-galactoside (Fosmire et al, 1992, Guarante et 
al, 1983, Tyagi et al. 2002). 
(b) Liquid p-galactosidase assay 
To perform liquid P-galactosidase assay, 1.5 ml of transformed culture with 
required incubation of the drugs was centrifuged at 13, 000 rpm for 3 min and the 
pellet was washed with 1.5 ml of Z-buffer (60 mM Na2HP04, 40 mM NaHaPOA, 10 
mM KCI, 1 mM MgS04) having a pH value of 7. The pellet was finally dissolved in 300 
/il of Z-buffer. To permeabilize the yeast cells, microcentrifuge tubes containing yeast 
pellet with Z-buffer were frozen in liquid nitrogen and thawed at room temperature. 
Next, 700 ii\ of Z-buffer having 50 mM p-mercaptoethanol was added. To this, 160 |il 
of 0-nitrophenyl-D-galactoside (10 mg/ml, made in Z-buffer and along with 50 mM 3-
mercaptoethanol) was added, and the mixture was kept at 30° C till a yellow color 
developed in the mixture. Relative enzymatic activity was determined in three 
independent experiments, and used to calculate the standard deviation. The samples 
were processed together and were incubated for the same length of time. To stop 
the reaction, 400 \y\ of sodium carbonate (1 M) was added. Reaction tubes were 
centrifuged at 13000 rpm for 10 min, and the supernatant was transferred to 
cuvettes to calculate p-gal expression levels, which were determined by measuring 
absorbance at 420 nm (Tyagi et al, 2001, Surjit et al, 2004). 
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5.3 Results and Discussion 
5.3.1 Ceil division inhibition 
Exponentially growing sacchromyces cerevisae cell were grown in the presence 
of increasing amounts of EPI and MTX. After 3 hrs of incubation with drugs, 
concentration dependent decrease in cell density was observed (Fig. 5.1). The 
decrease in cellular density corresponds to dose dependent inhibition of cell growth. 
The concentration at which the cell division comes to 50 % halt is 5 ng/ml and 3 
|ig/ml for EPI and MTX respectively. We have also evaluated the effect of these drugs 
on the growth curve of the yeast by treating with 4 tig/ml of the drugs. On comparing 
the growth curve of treated cells with untreated cell (Fig. 5.2), we observed that the 
growth curve of the treated cells was shifted toward the lag phase as compared to 
the growth curve of the untreated cells. The shift observed found to be more 
pronounced in MTX treated cells, which illustrates its higher impact oh the growth 
cycle of the cells as compared to the EPI. The above two results illustrates the 
marked inhibition of cell division by the tested drugs, which was found to be more 
efficient in case of the MTX than EPI. The results suggest the probable interference of 
these drugs with vital processes required for duplication and cellular proliferation, 
which delayed the normal growth phase of the cells. 
5.3.2 Cell survival 
To detect the drug induced toxicity, the cells were treated with different 
concentration of these drugs. The cells plated after the 3 hrs incubation illustrates 
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Figure 5.1 Cell growth inhibition in saccharomyces cereviasae with increasing 
concentration of EPI and MTX. Culture conditions are explained in section 5.2.2. 
Means ± SD of at least three independent experiments are reported. 
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Figure 5.2 Representative growth curves of cells grown in the absence and presence 
of drugs. Comparative growth trends of the cells, showing the effect of drugs on 
growth phases of the cells. Results from three independent experiments reported as 
means ±SD. 
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Figure 5.3 Drug-Cell survival (%) relationship in AH109 strain of yeast after 3 hrs 
treatment with EP\ and MTX separately. Culture conditions are explained in section 
5.2.2. Means ± SD of at least three independent experiments are reported. 
140 
CfiapterS 
the effect of these drugs on cell physiology. Figure 5.3, depicts the resultant 
cytotoxicity on treatment with different concentration of EPi and MTX. The trends 
were considerably the same for both the drugs, though it differs in the cell sensitivity 
towards them. The most striking effect was the drastic deduction in cells ability to 
form colonies on 2 h incubation with the drugs indicating the general loss of viability. 
We also calculated the drug concentration at which colony forming unit (cfu) reduced 
to 50 % and found it to be 10 ng/ml and 8 |ig/ml for EPI and MTX both. Hence, the 
result shows its potent cytotoxicity and its high impact on cell physiology. 
5.3.3 Confocal laser scanning microscopy (CLSM) 
To determine whether, the growth inhibition by EPI and MTX is correlated with 
the accumulation of cells at a specific point during its proliferation. We estimated the 
DNA content of the cells grown with and without the presence of drugs. The cells 
stained with DNA binding dye were visualized by confocal microscopy (Fig. 5.4, A & 
B). The untreated control cells when compared with the drug treated cells were 
found with drastically reduced DNA content. The similar pattern in the cells treated 
with EPI and MTX was suggestive of the occurrence of cells in some cell cycle stage. 
The focused fluorescence suggesting chromatin condensation and some dispersed 
fluorescence signals indicating some fragmentation in the drug treated cells were 
the common features of an ordinary apoptotic cell, implicating the prolong exposure 
of the cells with drugs may result in apoptosis. 
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Figure 5.4(A) Confocal images of saccharomyces cerevisae cells in the absence and 
presence of epirubicin (EPI). Panel a & a', represents the untreated control cell grown 
in YPD media for 12 hrs. Panel b & b', represents the cells grown in the presence of 
the drug. 
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Figure 5.4(B) Confocal images of saccharomyces cerevisae cells in the absence and 
presence of mitoxantrone (MTX). Panel a & a', represents the untreated control cell 
grown in YPD media for 12 h. Panel b & b', represents the cells grown in the presence 
of the drug. 
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5.3.4 Cell Integrity 
Fluorescence measurements 
Since the drugs seems to affect the cellular viability and DNA content might be 
related to the accumulation of dead cells in EPI or MTX treated cultures. We 
therefore investigated the cell integrity in this experiment. The cells treated with or 
v»/ithout the drugs were stained with PI and scanned for the fluorescence emission 
after excitation at 490 nm. Figure 5.5 ( A & B), illustrates the dose dependent effect 
of the fluorescence of PI. The figure depicts the increase in the fluorescence on 
increasing the drug concentration. This increase in fluorescence corresponds to the 
increase cell injury that is caused by repairable membrane damage in the cellular 
permeability on treating with the drugs. During extended cultivation the control cells 
retained the impermeability to the PI, this further authenticate the drug induced 
permeability in the treated cells and not due the developmental stages of the cell. 
Its interaction with cellular membranes have been demonstrated to play a 
crucial role in the cytotoxicity induced by these drugs, as they are important 
structural and functional components of all cell types both as boundaries of cells or 
intracellular compartments and as the environment for enzymes involved in vital 
cellular processes. Plasma membrane is proved to be one of the important targets of 
the mechanism of action of the anthracyclines. In fact, several activities of the plasma 
membrane, such as lectin interactions (Murphree etal., 1976), glycoprotein synthesis 
(Kessel, 1979), phospholipid structure and organization (Tritton et al., 1978), fluidity 
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and expression of hormone receptors (Murphree & Tritton, 1979) seem to be 
modulated by anthracyclines. They proved to be genotoxic only In cellular systems, 
suggesting that metabolism of the drug is a necessary step leading to DNA damage 
(Ferguson & Turner, 1998). 
5.3.5 Effect of drugs on cell cycle distribution 
To determine whether treatment with drugs resulted in cell cycle redistribution, 
the yeast cell lines were treated at their respective IC12.5 and IC25 dose for 24 h and 
analyzed by flow cytometry as described in IVIethods section. Intercalation of the PI 
to the DNA of the cells in the sample allows for quantification of the number of cells 
in a specific cell-cycle phase via fluorescence after exposure to an argon laser. At 
least 10,000 cells were analyzed for each sample. All measurements were done with 
same instrument settings. This test was repeated in three separate runs for accuracy. 
Figure 5.6 (A & B), represents the events detected by the flow cytometer in the 
absence and presence of increasing concentration of EPI and MTX, respectively. The 
cytograms reported on the right hand side of the profiles represents an analysis of 
their respective cell complexity (with side scatter) and cell size (with forward scatter) 
of the haplodiploid population for cells treated with the drugs are compared. The 
complexity of the cells seems to decrease on increasing the concentration of the 
drugs as compared with the untreated ceils. This suggests that more number of cells 
are arrested at the initial phases of cell cycle, thereby minimizing the cellular 
complexity. Almost comparable cell size, found with the control and the drug 
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Figure 5.5(A) Representative plot of the relative fluorescence intensities of cells on 
epirubicin (EPI) treatment. The plot depicts the fluorescence intensities of 
isopropanol treated control and the tested sannples in the absence and presence of 
increasing concentration of the drug. The data presented is the mean ± SEM values 
from the three independent experiments. 
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Figure 5.5(B) Representative plot of the relative fluorescence intensities of cells on 
mitoxantrone (MIX) treatment. The plot depicts the fluorescence intensities of 
isopropanol treated control and the tested samples in the absence and presence of 
increasing concentration of the drug. The data presented is the mean ± SEM values 
from the three independent experiments 
147 
CfiapterS 
treatment rule out the presence of cell debris in the analyzed cell population 
(Ormerod et ai, 1995). The frequency histogram (Fig. 5.7, A & B), from FACS analysis 
illustrate a dose-dependent Gl and G2/M phase arrest in yeast cell. Table 5.1 (A & B), 
represents the phase distribution of cell after treatment with EPI and MTX, 
whichsuggest the highest number of cells were found in G l and S phase as well as in 
Gl and G2 phase on the treatment of the drugs respectively. There was no evidence 
of apoptotic peaks (left of the Go-Gl peak) with any of the drug treatment. The FACS 
analysis was repeated in triplicate, and the data revealed a statistically significant 
cell-cycle arrest with both the drugs, (P ^  0.005). Regulated progression through the 
cell cycle and its checkpoints is paramount to normal cell proliferation (Grana & 
Reddy, 1995). Deregulation of the cell cycle plays a fundamental role in 
carcinogenesis. The Gl and G2 phase checkpoints are necessary to prevent tumor 
cells from unmitigated cycling and proliferation. As from our results, EPI and MTX 
promote cell-cycle arrest and growth inhibition by forcing Gl and G2 phase arrests. 
Arrest of S phase suggests the blockage of synthetic phase, thereby minimizing the 
synthesis and doubling of metabolically important constituents required for 
proliferation and sustenance of cells. By promoting cell cycle arrest and subsequent 
growth inhibition, Cells containing damaged DNA are allowed to be checked and 
possibly undergo apoptosis (Schwartz & Shah, 2005). The significant increases in cell 
cycle arrest that we demonstrated on FACS analysis also suggest an effect on cell-
cycle regulatory. 
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Figure 5.6(A) Representative cytograms of the cells grown with and without the 
treatment of epirubicin (EPI). Panel a, depicts the untreated cells used as the control. 
Panel b & c, represents the cells grown with increasing concentration of the drug. 
Respective bivariate dot plots of cellular complexity (side scatter; SSC-H vs FL2-H) and 
cell size (forward scatter; FSC-H vs FL2-H) are reported on the right side of their 
respective cytogram. 
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Figure 5.6(B) Representative cytograms of the cells grown with and without the 
treatnnent of nriitoxantrone (MTX). Panel a, depicts the untreated cells used as the 
control. Panel b & c, represents the cells grown with increasing concentration of the 
drug. Respective bivariate dot plots of cellular complexity (side scatter; SSC-H vs FL2-
H) and cell size (forward scatter; FSC-H vs FL2-H) are reported on the right side of 
their respective cytogram. 
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Figure 5.7(A) Frequency histogram from the cytometric analysis of cells grown with 
and without epirubicin (EPI). Panel a, represents the untreated cells and panel b & c, 
represents the cell grown with increasing concentration of the drug. 
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Figure 5.7(B) Frequency histogram from the cytometric analysis of cells grown with 
and without mitoxantrone (MTX). Panel a, represents the untreated cells and panel b 
& c, represents the cell grown with increasing concentration of the drug. 
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Table: 5.1 
(A): Effect of epirubicin (EPI) on cell cycle distribution 
Drug cone. {% cell distribution) 
(^g/ml) Gl S G2 
0.0 38 28 34 
2.5 42 40 18 
5.0 52 44 04 
(B): Effect of mitoxantrone (MTXI) on cell cycle distribution 
Drug cone. (% cell distribution) 
(pig/ml) Gl S G2 
0.0 38 28 34 
2.5 40 10 45 
5.0 42 05 57 
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proteins. Balance between cydins and CDKIs help to determine the clock-work 
progression through the cell-cycle. Binding of cydins and cydin-dependent-kinases 
promote cell-cycle transitions. The cdc2-cyclin Bl complex plays an important role in 
regulation of the G2/M phase gap and Gl phase progression is determined by cydins 
Dl and E in conjunction with CDK2 activity (Grana & Reddy, 1995). Hence, the 
significant increase in cell cycle arrest on Increasing the drug concentration suggests 
the effect of EPI and MTX on the cell cycle regulatory proteins. 
5.3.6 Yeast two hybrid system 
To study the interaction of EPI and MTX with the complex machinery of invivo 
systems, we selected the yeast two hybrid system to model the all types of possible 
interactions: protein-protein and protein DNA etc. Also it would give an idea about 
the effect of these drugs on the gene expression. 
Colony lift (filter) assay was carried out to see the effect of EPI and MTX on the 
expression on lac I gene fused with GAL4 DNA-binding domain. The effect of drugs 
on the gene expression was determined by analyzing the blue colour due to 3-
galactosidase activity. Figure 5.8 (A & B), shows the representative colony lifts in the 
absence and presence of the tested drugs. The result shows the drastic diminution of 
the colour on the treatment of cells with 4 |ig/ml of the drugs. The negative control 
shows no back ground in the experimental condition of 1 hrs incubation period with 
substrate for the present study. The results show the clear indication of the 
interaction of these drugs with gene expression. 
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Furthermore, we quantify the effect of EPI and MIX on enzyme activity by liquid 
P-galactosidase assay. In this experiment the cell suspension culture were treated 
with different concentration of the drugs. The negative (untransformed strain) and 
positive (transformed strain without drug) controls were set to accurately evaluate 
the enzyme activity and the mean relative 3-galactosidase activities are shown in 
figure 5.9 (A & B), which illustrates the drastic reduction in the enzyme activity on 
treatment with the drugs. The reduction was found to be dose dependent, which 
decreases with increase in the drug concentration. The trend was found comparable 
for both EPI and MTX, though the decrease in color formation was more pronounced 
on MTX treatment with that of EPI. After the drug treatment the cells were harvested 
and washed with the PBS to wash out the drug to eliminate the possibility of the 
enzyme inhibition by these drugs. Hence, we can correlate the reduction in the 
enzyme activity with repression oi lac Z gene. 
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Figure 5.8(A) Representative spots for colony lift assay. Expression of lac I gene in 
yeast two hybrid system in the absence and presence of increasing concentration of 
epirubicin (EPI), show as a function of 3-galactosidase activity. Colony of host strain 
depicts the untransformed cell used as the blank for background/ innate colour of 
the cells. 
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Figure 5.8(B) Representative spots for colony lift assay. Expression of lac Z gene in 
yeast two hybrid system in the absence and presence of increasing concentration of 
mitoxantrone (MTX), show as a function of 3-galactosidase activity. Colony of host 
strain depicts the untransformed ceil used as the blank for background/ innate colour 
of the cells. 
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Figure 5.9(A) Effect of epirubicin (EPI) on Pgalactosidase activity. Representative plot 
of the enzyme activity in absence and presence of drugs, correlating drug induced 
gene repression. The values plotted here are corrected by subtracting the blank from 
the studied samples and are the mean ± SD values of three independent 
experiments. 
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Figure 5.9(B) Effect of mitoxantrone (MTX) on p-galactosidase activity. 
Representative plot of the enzyme activity in absence and presence of drugs, 
correlating drug induced gene repression. The values plotted here are corrected by 
subtracting the blank from the studied samples and are the mean ± SD values of 
three independent experiments. 
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This study established the interaction of epirubicin (EPI) and 
nnitoxantrone (MTX) with histone core and more specifically histone H3. As 
histone H3 dynamically participate in the histone modification especially 
acetylation. Hence, the results implicate the hinderence in the acetylation 
process of lysine by binding on the histone protein. Docking studies place the 
drugs near the lysine 9 and 14 of histone H3, which may cause steric hinderence 
for the enzymatic machinery to approach the lysines or making the lysine less 
accessible for modification. The dose and time dependent inhibition of HATs 
activity reflects it interaction with the acetylation by inhibitng the HATs activity, 
thereby suggesting the maintenance of structural rigidity of nucleosome and 
retarding transcription. The drugs also show inhibitory effect against HDAC 
activity. HDAC inhibition, although is antagonastic to the HAT inhibition (gene 
repression), but at the same time it induces the expression of repressed genes 
that produce growth arrest, terminal differentiation, and/or apoptosis in 
carcinoma cells, thereby mainting the structural rigidity of the nucleus. The 
reduction in the in vivo acetylation level probed for histone H3 K9 and K14 
reflects the concentration dependent inhibitory effect of the drugs. Also, 
revealing the inhibition of acetyltransferses, suggesting global reduction in the 
acetylation level and thereby inhibiting the progression of transcription. Thus 
from this part of the study it is the first time we are correlating the 
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antiproliferative activity of antineoplastic drugs is also being regulated by histone 
modulation, especially acetylation. 
The binding of DNA studied here show high affinity with both the 
drugs though the drugs differ in their stoichiometry of 2:1 and 1:1 with EPI and 
MTX, respectively. We have also shown for the first time that these drugs can 
bind directly with the DNA-backbone, resulting in conformation transition of the 
DNA conformation. Several important aspects of this DNA-binding have been 
highlighted in this study such as: (a) the binding constants and the binding site 
size have been determined which show that these drug-DNA complexes bind 
strongly with the DNA; (b) the binding of these drugs are entropically driven, 
stabilized by hydrophobic interactions which itself is not a very common 
phenomena; and (c) analysis of the thermodynamic parameters and 
competitiveness of binding with EtBr followed by fluorescence studies and CD 
data points to a similar binding mode for both the drugs with DNA which could 
be intercalation; (d) FTIR and molecular modeling suggested the GC base 
specificity. The drug-DNA complexes studies are also suggestive to act as 
potential transcription inhibitors, because of its ability to bind consensus 
transcription factor binding motif and retarding the transcription factor (TF) 
assembly. 
In summing up, the biological effectiveness of EPI and MTX in the 
yeast S.cerevisiae proved to be strictly dependent on cell-specific 
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physiological/biochemical conditions, DNA condensation, damage, cell cycle 
arrest and cell membrane damage. Our study showed that these drugs inhibited 
the growth and reduces cell viability. The drugs induced cell specific arrest and 
affects membrane integrity, which finally will led to apoptosis in drug treated 
cells. Epirubicin (EPI) and mitoxantrone (MTX) might represent these effects 
through numerous mechanisms at different levels. Although many details of the 
effects of these potentially effective drugs are still poorly understood, the in vitro 
findings in the present study offer a significant groundwork for future 
understanding of the repression or derepression of transcription process in the 
presence of antineoplastic drugs. Furthermore, the yeast S.cerevisiae, a versatile 
eukaryotic system, was confirmed to be useful in further clarifying basic cellular 
mechanisms mediating the biological action of anticancer drugs and 
understanding the possible modulation of drug action by a holistic interaction of 
many cellular systems. There may, of course, be limitations to the utility of yeast 
as a mammal surrogate, due to differences in the molecular environment and the 
more complex genetic interactions in mammals. However, S.cerevisiae could be 
proposed as a cell model in the early studies of new drugs to provide rapid 
screening of the different biological activities of chemicals 
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^^yipen4ix 
Jippendix. 
(A) Composition of solutions for protein estimation 
The Copper reagent was prepared by mixing A, B and C in the ratio 
(98:1:1). The composition of solution A, B and C are as follows: 
Solution A: 2% Na2C03 in 0.1 M NaOH 
Solution B: 1% CuS04 in diHzO 
Solution C: 2% sodium potassium tartrate (NaKC4H406» 4H2O). 
Standard protein estimation protocol was followed and BSA was used as 
standard. 
(B) Composition of TAE buffer 
The composition of TAE buffer for agarose gel electrophoresis is as follows: 
Tris-acetate: 0.04 M 
EDTA: 0.001 M 
Final pH is 8.0 at room temperature 
(C) Composition of TBS-T 
Tris: 20 ml^ 
KCl: 1.3 mM 
NaCl: 135 mM 
Tween 20: 0.05% 
pH 7,4 at room temperature 
(D) Composition of YPD media 
The composition of YPD media is as follows: 
Component gms/1 
170 
Jippendlx_ 
Yeast extract 10.0 
Peptone 20.0 
Dextrose 20.0 
(E) Composition of PBS 
Na2HP04: 3.2 mM 
KH2P04: 0.5 mM 
KG: 1.3 mM 
NaCl: 135 mM 
pH 7.4 at room temperature 
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